http://www.odeo.com/channels/8011-MicrobeWorld-s-Meet-the-Scientist-Podcast FLPRadio no At Meet the Scientist, we want to reveal more about scientists, the work they do, and what makes them tick. We will ask them what they are up to now and what is next. How is the science moving forward to solve some of the intractable problems of our times? What keeps them going in a tough, competitive field? What do they see for the future of research, education, and training? We hope to show you a glimpse of what scientists are really like and what is going on in cutting-edge research today. MicrobeWorld's Meet the Scientist is brought to you by the American Society for Microbiology. Composed of over 42,000 scientists and health professionals, ASM's mission is to advance the microbial sciences as a vehicle for the improvement of health and economical and environmental well-being worldwide. For more information, visit us on the web at www.microbeworld.org. At Meet the Scientist, we want to reveal more about scientists, the work they do, and what makes them tick. We will ask them what they are up to now and what is next. How is the science moving forward to solve some of the intractable problems of our times? What keeps them going in a tough, competitive field? What do they see for the future of research, education, and training? We hope to show you a glimpse of what scientists are really like and what is going on in cutting-edge research today. MicrobeWorld's Meet the Scientist is brought to you by the American Society for Microbiology. Composed of over 42,000 scientists and health professionals, ASM's mission is to advance the microbial sciences as a vehicle for the improvement of health and economical and environmental well-being worldwide. For more information, visit us on the web at www.microbeworld.org. A Podcast from the American Society for Microbiology en 40 Wed, 04 Nov 2009 18:04:12 -0800 Wed, 04 Nov 2009 18:04:12 -0800 Science http://www.odeo.com/episodes/25401100-MTS38-Jonathan-Eisen-An-Embarrassment-of-Genomes Jonathan Eisen is a professor at the University of California, Davis Genome Center. Over the course of his career, he has pioneered new ways of sequencing microbial genomes and analyzing them. I talked to Eisen about some of the weirdest creatures he's studied, such as bacteria that only live on the bellies of worms at the bottom of the ocean, and how we may be able to exploit their genomes for our own benefit. We also discussed the new movement for open access to scientific literature, a subject that's a particular passion of Eisen, who is academic editor in chief at the open-access journal PLOS Biology. Jonathan Eisen is a professor at the University of California, Davis Genome Center. Over the course of his career, he has pioneered new ways of sequencing microbial genomes and analyzing them. I talked to Eisen about some of the weirdest creatures he's studied, such as bacteria that only live on the bellies of worms at the bottom of the ocean, and how we may be able to exploit their genomes for our own benefit. We also discussed the new movement for open access to scientific literature, a subject that's a particular passion of Eisen, who is academic editor in chief at the open-access journal PLOS Biology. Jonathan Eisen is a professor at the University of California, Davis Genome Center. Over the course of his career, he has pioneered new ways of sequencing microbial genomes and analyzing them. I talked to Eisen about some of the weirdest creatures he's studied, such as bacteria that only live on the bellies of worms at the bottom of the ocean, and how we may be able to exploit their genomes for our own benefit. We also discussed the new movement for open access to scientific literature, a subject that's a particular passion of Eisen, who is academic editor in chief at the open-access journal PLOS Biology. tag:odeo.com,2009-11-04,25401100 Wed, 04 Nov 2009 18:04:12 -0800 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/25358816-MTS37-Hazel-Barton-Cave-Dwellers Hazel Barton is the Ashland Professor of Integrative Science at Northern Kentucky. She explores some of the world's most remote caves to study the remarkable diversity of microbes that thrive in their dark recesses. I spoke to Barton about how she first became captivated by these bizarre organisms, what it's like to do delicate microbiology when you're hip-deep in mud, and why she wants to explore caves on Mars in search of Martians. Hazel Barton is the Ashland Professor of Integrative Science at Northern Kentucky. She explores some of the world's most remote caves to study the remarkable diversity of microbes that thrive in their dark recesses. I spoke to Barton about how she first became captivated by these bizarre organisms, what it's like to do delicate microbiology when you're hip-deep in mud, and why she wants to explore caves on Mars in search of Martians. Hazel Barton is the Ashland Professor of Integrative Science at Northern Kentucky. She explores some of the world's most remote caves to study the remarkable diversity of microbes that thrive in their dark recesses. I spoke to Barton about how she first became captivated by these bizarre organisms, what it's like to do delicate microbiology when you're hip-deep in mud, and why she wants to explore caves on Mars in search of Martians. tag:odeo.com,2009-10-23,25358816 Fri, 23 Oct 2009 12:04:12 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/25259321-MTS36-Dennis-Bray-Living-Computers Dennis Bray is an active professor emeritus in both the Department of Physiology and Department of Neuroscience at the University of Cambridge. He studies the behavior of microbes--how they "decide" where to swim, when to divide, and how best to manage the millions of chemical reactions taking place inside their membranes. For Bray, microbes are tiny, living computers, with genes and proteins serving the roles of microprocessors. In this interview, I talked with Bray about his provocative new book, Wetware: A Living Computer Inside Every Cell. Dennis Bray is an active professor emeritus in both the Department of Physiology and Department of Neuroscience at the University of Cambridge. He studies the behavior of microbes--how they "decide" where to swim, when to divide, and how best to manage the millions of chemical reactions taking place inside their membranes. For Bray, microbes are tiny, living computers, with genes and proteins serving the roles of microprocessors. In this interview, I talked with Bray about his provocative new book, Wetware: A Living Computer Inside Every Cell. Dennis Bray is an active professor emeritus in both the Department of Physiology and Department of Neuroscience at the University of Cambridge. He studies the behavior of microbes--how they "decide" where to swim, when to divide, and how best to manage the millions of chemical reactions taking place inside their membranes. For Bray, microbes are tiny, living computers, with genes and proteins serving the roles of microprocessors. In this interview, I talked with Bray about his provocative new book, Wetware: A Living Computer Inside Every Cell. tag:odeo.com,2009-10-09,25259321 Fri, 09 Oct 2009 10:04:12 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/25110093-MTS35-Michael-Cunliffe-The-Ocean-s-Living-Skin Michael Cunliffe is a microbiologist in the Department of Biological Sciences at the University of Warwick in England. He studies the microbes that live in the thin layer of water at the very surface of the ocean. His research is shedding light on an ecosystem that's both mysterious and huge, spanning three-quarters of the surface of the planet.In this interview, I talked with Cunliffe about the discovery of this sea-surface ecosystem, and the influence it has over the climate. Michael Cunliffe is a microbiologist in the Department of Biological Sciences at the University of Warwick in England. He studies the microbes that live in the thin layer of water at the very surface of the ocean. His research is shedding light on an ecosystem that's both mysterious and huge, spanning three-quarters of the surface of the planet.In this interview, I talked with Cunliffe about the discovery of this sea-surface ecosystem, and the influence it has over the climate. Michael Cunliffe is a microbiologist in the Department of Biological Sciences at the University of Warwick in England. He studies the microbes that live in the thin layer of water at the very surface of the ocean. His research is shedding light on an ecosystem that's both mysterious and huge, spanning three-quarters of the surface of the planet.In this interview, I talked with Cunliffe about the discovery of this sea-surface ecosystem, and the influence it has over the climate. tag:odeo.com,2009-09-11,25110093 Fri, 11 Sep 2009 11:00:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/25037705-MTS34-Pratik-Shah-Combatting-Pathogens-with-Polyamines Pratik Shah is a graduate student in the Department of Microbiology at the University of Mississippi Medical Center in Jackson, and he’s a 2009 recipient of ASM’s Raymond W. Sarber award, granted to recognize students for research excellence and potential. His research focuses on polyamines and polyamine biosynthesis and transport systems in Streptococcus pneumoniae. He’s studying polyamines with the goal of finding potential targets for pneumococcal vaccines and prophylactic interventions against pneumococcal disease. In this interview, I talked with Pratik about why polyamines may hold the key for new ways to combat pathogens, his plans for the future, and about advice he would give to young people considering grad school. Pratik Shah is a graduate student in the Department of Microbiology at the University of Mississippi Medical Center in Jackson, and he’s a 2009 recipient of ASM’s Raymond W. Sarber award, granted to recognize students for research excellence and potential. His research focuses on polyamines and polyamine biosynthesis and transport systems in Streptococcus pneumoniae. He’s studying polyamines with the goal of finding potential targets for pneumococcal vaccines and prophylactic interventions against pneumococcal disease. In this interview, I talked with Pratik about why polyamines may hold the key for new ways to combat pathogens, his plans for the future, and about advice he would give to young people considering grad school. Pratik Shah is a graduate student in the Department of Microbiology at the University of Mississippi Medical Center in Jackson, and he’s a 2009 recipient of ASM’s Raymond W. Sarber award, granted to recognize students for research excellence and potential. His research focuses on polyamines and polyamine biosynthesis and transport systems in Streptococcus pneumoniae. He’s studying polyamines with the goal of finding potential targets for pneumococcal vaccines and prophylactic interventions against pneumococcal disease. In this interview, I talked with Pratik about why polyamines may hold the key for new ways to combat pathogens, his plans for the future, and about advice he would give to young people considering grad school. tag:odeo.com,2009-08-28,25037705 Fri, 28 Aug 2009 11:00:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24955292-MTS33-Abigail-Salyers-The-Art-of-Teaching-Science Abigail Salyers is a Professor of Microbiology and the G. William Arends Professor of Molecular and Cell Biology at the University of Illinois at Urbana-Champaign, and her research focuses on the ecology of microorganisms in the human body and the comings and goings of antibiotic resistance genes, particularly genes in Bacteroides species. Dr. Salyers is ASM’s 2009 Graduate Microbiology Teaching Awardee. If you’ve ever tried teaching or mentoring, you know it’s not always easy, but for an eminent scientist, teaching at the undergraduate or graduate level must be incredibly difficult. After all, once you reach a certain level of knowledge in any field, it can be hard to relate your knowledge to people who know relatively little about it. Dr. Salyers has tackled 100-level biology courses with as many as 300 students, taught one-on-one at the lab bench, and been an instructor at an intensive summer course in microbial diversity, all while rising to the top of her field in research. In ... Abigail Salyers is a Professor of Microbiology and the G. William Arends Professor of Molecular and Cell Biology at the University of Illinois at Urbana-Champaign, and her research focuses on the ecology of microorganisms in the human body and the comings and goings of antibiotic resistance genes, particularly genes in Bacteroides species. Dr. Salyers is ASM’s 2009 Graduate Microbiology Teaching Awardee. If you’ve ever tried teaching or mentoring, you know it’s not always easy, but for an eminent scientist, teaching at the undergraduate or graduate level must be incredibly difficult. After all, once you reach a certain level of knowledge in any field, it can be hard to relate your knowledge to people who know relatively little about it. Dr. Salyers has tackled 100-level biology courses with as many as 300 students, taught one-on-one at the lab bench, and been an instructor at an intensive summer course in microbial diversity, all while rising to the top of her field in research. In this interview, I talked with Dr. Salyers about the most influential teacher in her own life (you might be surprised to learn who that is), about whether antibiotic resistance is getting the kind of play it deserves, and about why the baboon vagina is an interesting study system. Abigail Salyers is a Professor of Microbiology and the G. William Arends Professor of Molecular and Cell Biology at the University of Illinois at Urbana-Champaign, and her research focuses on the ecology of microorganisms in the human body and the comings and goings of antibiotic resistance genes, particularly genes in Bacteroides species. Dr. Salyers is ASM’s 2009 Graduate Microbiology Teaching Awardee. If you’ve ever tried teaching or mentoring, you know it’s not always easy, but for an eminent scientist, teaching at the undergraduate or graduate level must be incredibly difficult. After all, once you reach a certain level of knowledge in any field, it can be hard to relate your knowledge to people who know relatively little about it. Dr. Salyers has tackled 100-level biology courses with as many as 300 students, taught one-on-one at the lab bench, and been an instructor at an intensive summer course in microbial diversity, all while rising to the top of her field in research. In this interview, I talked with Dr. Salyers about the most influential teacher in her own life (you might be surprised to learn who that is), about whether antibiotic resistance is getting the kind of play it deserves, and about why the baboon vagina is an interesting study system. tag:odeo.com,2009-08-13,24955292 Thu, 13 Aug 2009 14:00:40 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24961937-MTS33-Abigail-Salyers-The-Art-of-Teaching-Science Abigail Salyers is a Professor of Microbiology and the G. William Arends Professor of Molecular and Cell Biology at the University of Illinois at Urbana-Champaign, and her research focuses on the ecology of microorganisms in the human body and the comings and goings of antibiotic resistance genes, particularly genes in Bacteroides species. Dr. Salyers is ASM’s 2009 Graduate Microbiology Teaching Awardee. If you’ve ever tried teaching or mentoring, you know it’s not always easy, but for an eminent scientist, teaching at the undergraduate or graduate level must be incredibly difficult. After all, once you reach a certain level of knowledge in any field, it can be hard to relate your knowledge to people who know relatively little about it. Dr. Salyers has tackled 100-level biology courses with as many as 300 students, taught one-on-one at the lab bench, and been an instructor at an intensive summer course in microbial diversity, all while rising to the top of her field in research. In ... Abigail Salyers is a Professor of Microbiology and the G. William Arends Professor of Molecular and Cell Biology at the University of Illinois at Urbana-Champaign, and her research focuses on the ecology of microorganisms in the human body and the comings and goings of antibiotic resistance genes, particularly genes in Bacteroides species. Dr. Salyers is ASM’s 2009 Graduate Microbiology Teaching Awardee. If you’ve ever tried teaching or mentoring, you know it’s not always easy, but for an eminent scientist, teaching at the undergraduate or graduate level must be incredibly difficult. After all, once you reach a certain level of knowledge in any field, it can be hard to relate your knowledge to people who know relatively little about it. Dr. Salyers has tackled 100-level biology courses with as many as 300 students, taught one-on-one at the lab bench, and been an instructor at an intensive summer course in microbial diversity, all while rising to the top of her field in research. In this interview, I talked with Dr. Salyers about the most influential teacher in her own life (you might be surprised to learn who that is), about whether antibiotic resistance is getting the kind of play it deserves, and about why the baboon vagina is an interesting study system. Abigail Salyers is a Professor of Microbiology and the G. William Arends Professor of Molecular and Cell Biology at the University of Illinois at Urbana-Champaign, and her research focuses on the ecology of microorganisms in the human body and the comings and goings of antibiotic resistance genes, particularly genes in Bacteroides species. Dr. Salyers is ASM’s 2009 Graduate Microbiology Teaching Awardee. If you’ve ever tried teaching or mentoring, you know it’s not always easy, but for an eminent scientist, teaching at the undergraduate or graduate level must be incredibly difficult. After all, once you reach a certain level of knowledge in any field, it can be hard to relate your knowledge to people who know relatively little about it. Dr. Salyers has tackled 100-level biology courses with as many as 300 students, taught one-on-one at the lab bench, and been an instructor at an intensive summer course in microbial diversity, all while rising to the top of her field in research. In this interview, I talked with Dr. Salyers about the most influential teacher in her own life (you might be surprised to learn who that is), about whether antibiotic resistance is getting the kind of play it deserves, and about why the baboon vagina is an interesting study system. tag:odeo.com,2009-08-13,24961937 Thu, 13 Aug 2009 10:34:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24920110-MTS10-Anthony-Maurelli-Black-Holes-and-Antivirulence-Genes Tony Maurelli is a professor of microbiology and immunology in the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. Dr. Maurelli’s major research interest lies in the genetics of bacterial pathogenesis – the genetic nuts and bolts of how bacteria infect humans and make us sick. Dr. Maurelli’s work has uncovered “antivirulence genes” in Shigella flexneri, a major cause of dysentery and food borne illness. This is an interesting concept: antivirulence genes undermine pathogenicity, so they must be broken or dropped from the genome for a bacterium to take good advantage of a host and cause disease. These genes are a hindrance, so to become an effective pathogen, Shigella must stop using them. In this interview, Dr. Merry Buckley talks with Dr. Maurelli about antivirulence genes, whether the naming system for bacteria should be fixed, and his favorite microbe. Tony Maurelli is a professor of microbiology and immunology in the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. Dr. Maurelli’s major research interest lies in the genetics of bacterial pathogenesis – the genetic nuts and bolts of how bacteria infect humans and make us sick. Dr. Maurelli’s work has uncovered “antivirulence genes” in Shigella flexneri, a major cause of dysentery and food borne illness. This is an interesting concept: antivirulence genes undermine pathogenicity, so they must be broken or dropped from the genome for a bacterium to take good advantage of a host and cause disease. These genes are a hindrance, so to become an effective pathogen, Shigella must stop using them. In this interview, Dr. Merry Buckley talks with Dr. Maurelli about antivirulence genes, whether the naming system for bacteria should be fixed, and his favorite microbe. Tony Maurelli is a professor of microbiology and immunology in the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. Dr. Maurelli’s major research interest lies in the genetics of bacterial pathogenesis – the genetic nuts and bolts of how bacteria infect humans and make us sick. Dr. Maurelli’s work has uncovered “antivirulence genes” in Shigella flexneri, a major cause of dysentery and food borne illness. This is an interesting concept: antivirulence genes undermine pathogenicity, so they must be broken or dropped from the genome for a bacterium to take good advantage of a host and cause disease. These genes are a hindrance, so to become an effective pathogen, Shigella must stop using them. In this interview, Dr. Merry Buckley talks with Dr. Maurelli about antivirulence genes, whether the naming system for bacteria should be fixed, and his favorite microbe. tag:odeo.com,2009-08-06,24920110 Thu, 06 Aug 2009 13:23:50 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24920087-MTS29-Christine-Biron-The-Innate-Immune-System Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology. When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate an... Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology. When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate and adaptive immune responses. In this interview, I talked with Dr. Biron about our increasing awareness of the innate immune system, why it’s important to bring microbiologists and immunologists together under one big tent, and why it’s best that a battle between a virus and a host ends not in victory for one and defeat for the other, but in détente. Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology. When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate and adaptive immune responses. In this interview, I talked with Dr. Biron about our increasing awareness of the innate immune system, why it’s important to bring microbiologists and immunologists together under one big tent, and why it’s best that a battle between a virus and a host ends not in victory for one and defeat for the other, but in détente. tag:odeo.com,2009-08-06,24920087 Thu, 06 Aug 2009 13:23:48 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24920088-MTS28-Joseph-DeRisi-New-Tech-Approaches-to-Infectious-Disease Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career. Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies a... Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career. Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies and control measures to help both captive birds and birds in the wild can’t be far behind. In this interview, I asked Dr. DeRisi whether he’s interested in putting the microarray approach to virus discovery to work in uncovering the causes of some human illnesses, especially those diseases we suspect might be spread by viruses, but for which we’ve never found a virus responsible. He has some very interesting ideas for where to start. We also talked about his work on identifying the SARS virus, and a new approach in the ongoing fight against malaria. ID3 Podcast Image Provided by James Gathany Courtesy of the CDC. Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career. Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies and control measures to help both captive birds and birds in the wild can’t be far behind. In this interview, I asked Dr. DeRisi whether he’s interested in putting the microarray approach to virus discovery to work in uncovering the causes of some human illnesses, especially those diseases we suspect might be spread by viruses, but for which we’ve never found a virus responsible. He has some very interesting ideas for where to start. We also talked about his work on identifying the SARS virus, and a new approach in the ongoing fight against malaria. ID3 Podcast Image Provided by James Gathany Courtesy of the CDC. tag:odeo.com,2009-08-06,24920088 Thu, 06 Aug 2009 13:23:48 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24882808-MTS32-Arthur-Guruswamy-Mycobacterial-and-Fungal-Pathogens Arthur Guruswamy is a clinical microbiologist in Virginia’s Department of General Services Division of Consolidated Laboratory Services and the winner of ASM's Scherago-Rubin Award in recognition of an outstanding, bench-level clinical microbiologist. His particular interest lies in mycobacterial and fungal diseases, including tuberculosis. In his work, Mr. Guruswamy places a lot of emphasis on helping others. A while back, he traveled to his native Sri Lanka to train clinic staff in the use of a rapid, low tech method for identifying cases of tuberculosis. Using this method has probably saved many lives, since staff Mr. Guruswamy trained can now treat their patients quickly and avoid the three to four week wait for culture results. Mr. Guruswamy is also involved in ASM’s Minority Mentoring Program so he can offer younger scientists the kind of assistance he says he got from other ASM members back at the beginning of his own career, when he arrive in the United States wi... Arthur Guruswamy is a clinical microbiologist in Virginia’s Department of General Services Division of Consolidated Laboratory Services and the winner of ASM's Scherago-Rubin Award in recognition of an outstanding, bench-level clinical microbiologist. His particular interest lies in mycobacterial and fungal diseases, including tuberculosis. In his work, Mr. Guruswamy places a lot of emphasis on helping others. A while back, he traveled to his native Sri Lanka to train clinic staff in the use of a rapid, low tech method for identifying cases of tuberculosis. Using this method has probably saved many lives, since staff Mr. Guruswamy trained can now treat their patients quickly and avoid the three to four week wait for culture results. Mr. Guruswamy is also involved in ASM’s Minority Mentoring Program so he can offer younger scientists the kind of assistance he says he got from other ASM members back at the beginning of his own career, when he arrive in the United States with less than $50 in his pocket. In this interview, I asked Mr. Guruswamy about his work at the state lab in Virginia, about tuberculosis in this country, and about why he saw more unusual clinical cases during his time working at the Mayo Clinic in Minnesota than he has during any other phase of his career. Arthur Guruswamy is a clinical microbiologist in Virginia’s Department of General Services Division of Consolidated Laboratory Services and the winner of ASM's Scherago-Rubin Award in recognition of an outstanding, bench-level clinical microbiologist. His particular interest lies in mycobacterial and fungal diseases, including tuberculosis. In his work, Mr. Guruswamy places a lot of emphasis on helping others. A while back, he traveled to his native Sri Lanka to train clinic staff in the use of a rapid, low tech method for identifying cases of tuberculosis. Using this method has probably saved many lives, since staff Mr. Guruswamy trained can now treat their patients quickly and avoid the three to four week wait for culture results. Mr. Guruswamy is also involved in ASM’s Minority Mentoring Program so he can offer younger scientists the kind of assistance he says he got from other ASM members back at the beginning of his own career, when he arrive in the United States with less than $50 in his pocket. In this interview, I asked Mr. Guruswamy about his work at the state lab in Virginia, about tuberculosis in this country, and about why he saw more unusual clinical cases during his time working at the Mayo Clinic in Minnesota than he has during any other phase of his career. tag:odeo.com,2009-07-29,24882808 Wed, 29 Jul 2009 16:11:09 -0700 no MicrobeWorld's Meet the Scientist Podcast Science, clinic, award, disease, program, sri lanka, tuberculosis, mentor, mayo, minority, ASM, pathogen, guruswamy, scherago-rubin, fungal, microbiologist, mycobacterial http://www.odeo.com/episodes/24920085-MTS32-Arthur-Guruswamy-Mycobacterial-and-Fungal-Pathogens Arthur Guruswamy is a clinical microbiologist in Virginia’s Department of General Services Division of Consolidated Laboratory Services and the winner of ASM's Scherago-Rubin Award in recognition of an outstanding, bench-level clinical microbiologist. His particular interest lies in mycobacterial and fungal diseases, including tuberculosis. In his work, Mr. Guruswamy places a lot of emphasis on helping others. A while back, he traveled to his native Sri Lanka to train clinic staff in the use of a rapid, low tech method for identifying cases of tuberculosis. Using this method has probably saved many lives, since staff Mr. Guruswamy trained can now treat their patients quickly and avoid the three to four week wait for culture results. Mr. Guruswamy is also involved in ASM’s Minority Mentoring Program so he can offer younger scientists the kind of assistance he says he got from other ASM members back at the beginning of his own career, when he arrive in the United States with less than... Arthur Guruswamy is a clinical microbiologist in Virginia’s Department of General Services Division of Consolidated Laboratory Services and the winner of ASM's Scherago-Rubin Award in recognition of an outstanding, bench-level clinical microbiologist. His particular interest lies in mycobacterial and fungal diseases, including tuberculosis. In his work, Mr. Guruswamy places a lot of emphasis on helping others. A while back, he traveled to his native Sri Lanka to train clinic staff in the use of a rapid, low tech method for identifying cases of tuberculosis. Using this method has probably saved many lives, since staff Mr. Guruswamy trained can now treat their patients quickly and avoid the three to four week wait for culture results. Mr. Guruswamy is also involved in ASM’s Minority Mentoring Program so he can offer younger scientists the kind of assistance he says he got from other ASM members back at the beginning of his own career, when he arrive in the United States with less than $50 in his pocket. In this interview, I asked Mr. Guruswamy about his work at the state lab in Virginia, about tuberculosis in this country, and about why he saw more unusual clinical cases during his time working at the Mayo Clinic in Minnesota than he has during any other phase of his career. Arthur Guruswamy is a clinical microbiologist in Virginia’s Department of General Services Division of Consolidated Laboratory Services and the winner of ASM's Scherago-Rubin Award in recognition of an outstanding, bench-level clinical microbiologist. His particular interest lies in mycobacterial and fungal diseases, including tuberculosis. In his work, Mr. Guruswamy places a lot of emphasis on helping others. A while back, he traveled to his native Sri Lanka to train clinic staff in the use of a rapid, low tech method for identifying cases of tuberculosis. Using this method has probably saved many lives, since staff Mr. Guruswamy trained can now treat their patients quickly and avoid the three to four week wait for culture results. Mr. Guruswamy is also involved in ASM’s Minority Mentoring Program so he can offer younger scientists the kind of assistance he says he got from other ASM members back at the beginning of his own career, when he arrive in the United States with less than $50 in his pocket. In this interview, I asked Mr. Guruswamy about his work at the state lab in Virginia, about tuberculosis in this country, and about why he saw more unusual clinical cases during his time working at the Mayo Clinic in Minnesota than he has during any other phase of his career. tag:odeo.com,2009-07-29,24920085 Wed, 29 Jul 2009 14:00:40 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24916369-MTS32-Arthur-Guruswamy-Mycobacterial-and-Fungal-Pathogens Arthur Guruswamy is a clinical microbiologist in Virginia’s Department of General Services Division of Consolidated Laboratory Services and the winner of ASM's Scherago-Rubin Award in recognition of an outstanding, bench-level clinical microbiologist. His particular interest lies in mycobacterial and fungal diseases, including tuberculosis. In his work, Mr. Guruswamy places a lot of emphasis on helping others. A while back, he traveled to his native Sri Lanka to train clinic staff in the use of a rapid, low tech method for identifying cases of tuberculosis. Using this method has probably saved many lives, since staff Mr. Guruswamy trained can now treat their patients quickly and avoid the three to four week wait for culture results. Mr. Guruswamy is also involved in ASM’s Minority Mentoring Program so he can offer younger scientists the kind of assistance he says he got from other ASM members back at the beginning of his own career, when he arrive in the United States with less than... Arthur Guruswamy is a clinical microbiologist in Virginia’s Department of General Services Division of Consolidated Laboratory Services and the winner of ASM's Scherago-Rubin Award in recognition of an outstanding, bench-level clinical microbiologist. His particular interest lies in mycobacterial and fungal diseases, including tuberculosis. In his work, Mr. Guruswamy places a lot of emphasis on helping others. A while back, he traveled to his native Sri Lanka to train clinic staff in the use of a rapid, low tech method for identifying cases of tuberculosis. Using this method has probably saved many lives, since staff Mr. Guruswamy trained can now treat their patients quickly and avoid the three to four week wait for culture results. Mr. Guruswamy is also involved in ASM’s Minority Mentoring Program so he can offer younger scientists the kind of assistance he says he got from other ASM members back at the beginning of his own career, when he arrive in the United States with less than $50 in his pocket. In this interview, I asked Mr. Guruswamy about his work at the state lab in Virginia, about tuberculosis in this country, and about why he saw more unusual clinical cases during his time working at the Mayo Clinic in Minnesota than he has during any other phase of his career. Arthur Guruswamy is a clinical microbiologist in Virginia’s Department of General Services Division of Consolidated Laboratory Services and the winner of ASM's Scherago-Rubin Award in recognition of an outstanding, bench-level clinical microbiologist. His particular interest lies in mycobacterial and fungal diseases, including tuberculosis. In his work, Mr. Guruswamy places a lot of emphasis on helping others. A while back, he traveled to his native Sri Lanka to train clinic staff in the use of a rapid, low tech method for identifying cases of tuberculosis. Using this method has probably saved many lives, since staff Mr. Guruswamy trained can now treat their patients quickly and avoid the three to four week wait for culture results. Mr. Guruswamy is also involved in ASM’s Minority Mentoring Program so he can offer younger scientists the kind of assistance he says he got from other ASM members back at the beginning of his own career, when he arrive in the United States with less than $50 in his pocket. In this interview, I asked Mr. Guruswamy about his work at the state lab in Virginia, about tuberculosis in this country, and about why he saw more unusual clinical cases during his time working at the Mayo Clinic in Minnesota than he has during any other phase of his career. tag:odeo.com,2009-07-29,24916369 Wed, 29 Jul 2009 14:00:40 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24916370-MTS31-Frances-Arnold-Engineering-Microbes Dr. Frances Arnold is a professor of Chemical Engineering and Biochemistry at the California Institute of Technology (most of us know it as Caltech). Dr. Arnold’s research focuses on evolutionary design of biological systems, an approach she is currently applying to engineer cellulases and cellulolytic enzymes for manufacturing biofuels. This country’s energy security can look pretty bleak when you think about it: the need to address global warming, strife in oil-rich nations, and depletion of fossil fuels combine to paint an uncertain future, and although ethanol has a lot of friends in Iowa and D.C., ethanol isn’t going to end our energy woes. In the future, our energy supply will probably be cobbled together from a number of different fuels and sources. Dr. Arnold is interested in engineering microbes that can grant us a biofuel that packs more of a caloric punch than ethanol. She likes isobutanol, which can be converted into a fuel that’s more like the hydrocarbons we currently ... Dr. Frances Arnold is a professor of Chemical Engineering and Biochemistry at the California Institute of Technology (most of us know it as Caltech). Dr. Arnold’s research focuses on evolutionary design of biological systems, an approach she is currently applying to engineer cellulases and cellulolytic enzymes for manufacturing biofuels. This country’s energy security can look pretty bleak when you think about it: the need to address global warming, strife in oil-rich nations, and depletion of fossil fuels combine to paint an uncertain future, and although ethanol has a lot of friends in Iowa and D.C., ethanol isn’t going to end our energy woes. In the future, our energy supply will probably be cobbled together from a number of different fuels and sources. Dr. Arnold is interested in engineering microbes that can grant us a biofuel that packs more of a caloric punch than ethanol. She likes isobutanol, which can be converted into a fuel that’s more like the hydrocarbons we currently put into our fuel tanks. To develop proteins that make the comounds she wants the way she wants, Arnold and her team take a gene that needs tweaking to do the job, introduce directed mutations into it, and select the mutant proteins that do the job best. In this interview, I talked with Dr. Arnold about how she got into alternative energy during the Carter administration (and got out again during the Reagan administration), what she sees in the P450 enzyme, and how she explains her work to people outside her field. Dr. Frances Arnold is a professor of Chemical Engineering and Biochemistry at the California Institute of Technology (most of us know it as Caltech). Dr. Arnold’s research focuses on evolutionary design of biological systems, an approach she is currently applying to engineer cellulases and cellulolytic enzymes for manufacturing biofuels. This country’s energy security can look pretty bleak when you think about it: the need to address global warming, strife in oil-rich nations, and depletion of fossil fuels combine to paint an uncertain future, and although ethanol has a lot of friends in Iowa and D.C., ethanol isn’t going to end our energy woes. In the future, our energy supply will probably be cobbled together from a number of different fuels and sources. Dr. Arnold is interested in engineering microbes that can grant us a biofuel that packs more of a caloric punch than ethanol. She likes isobutanol, which can be converted into a fuel that’s more like the hydrocarbons we currently put into our fuel tanks. To develop proteins that make the comounds she wants the way she wants, Arnold and her team take a gene that needs tweaking to do the job, introduce directed mutations into it, and select the mutant proteins that do the job best. In this interview, I talked with Dr. Arnold about how she got into alternative energy during the Carter administration (and got out again during the Reagan administration), what she sees in the P450 enzyme, and how she explains her work to people outside her field. tag:odeo.com,2009-07-15,24916370 Wed, 15 Jul 2009 14:00:40 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24823417-MTS31-Frances-Arnold-Engineering-Microbes Dr. Frances Arnold is a professor of Chemical Engineering and Biochemistry at the California Institute of Technology (most of us know it as Caltech). Dr. Arnold’s research focuses on evolutionary design of biological systems, an approach she is currently applying to engineer cellulases and cellulolytic enzymes for manufacturing biofuels. This country’s energy security can look pretty bleak when you think about it: the need to address global warming, strife in oil-rich nations, and depletion of fossil fuels combine to paint an uncertain future, and although ethanol has a lot of friends in Iowa and D.C., ethanol isn’t going to end our energy woes. In the future, our energy supply will probably be cobbled together from a number of different fuels and sources. Dr. Arnold is interested in engineering microbes that can grant us a biofuel that packs more of a caloric punch than ethanol. She likes isobutanol, which can be converted into a fuel that’s more like the hy... Dr. Frances Arnold is a professor of Chemical Engineering and Biochemistry at the California Institute of Technology (most of us know it as Caltech). Dr. Arnold’s research focuses on evolutionary design of biological systems, an approach she is currently applying to engineer cellulases and cellulolytic enzymes for manufacturing biofuels. This country’s energy security can look pretty bleak when you think about it: the need to address global warming, strife in oil-rich nations, and depletion of fossil fuels combine to paint an uncertain future, and although ethanol has a lot of friends in Iowa and D.C., ethanol isn’t going to end our energy woes. In the future, our energy supply will probably be cobbled together from a number of different fuels and sources. Dr. Arnold is interested in engineering microbes that can grant us a biofuel that packs more of a caloric punch than ethanol. She likes isobutanol, which can be converted into a fuel that’s more like the hydrocarbons we currently put into our fuel tanks. To develop proteins that make the comounds she wants the way she wants, Arnold and her team take a gene that needs tweaking to do the job, introduce directed mutations into it, and select the mutant proteins that do the job best. In this interview, I talked with Dr. Arnold about how she got into alternative energy during the Carter administration (and got out again during the Reagan administration), what she sees in the P450 enzyme, and how she explains her work to people outside her field. Dr. Frances Arnold is a professor of Chemical Engineering and Biochemistry at the California Institute of Technology (most of us know it as Caltech). Dr. Arnold’s research focuses on evolutionary design of biological systems, an approach she is currently applying to engineer cellulases and cellulolytic enzymes for manufacturing biofuels. This country’s energy security can look pretty bleak when you think about it: the need to address global warming, strife in oil-rich nations, and depletion of fossil fuels combine to paint an uncertain future, and although ethanol has a lot of friends in Iowa and D.C., ethanol isn’t going to end our energy woes. In the future, our energy supply will probably be cobbled together from a number of different fuels and sources. Dr. Arnold is interested in engineering microbes that can grant us a biofuel that packs more of a caloric punch than ethanol. She likes isobutanol, which can be converted into a fuel that’s more like the hydrocarbons we currently put into our fuel tanks. To develop proteins that make the comounds she wants the way she wants, Arnold and her team take a gene that needs tweaking to do the job, introduce directed mutations into it, and select the mutant proteins that do the job best. In this interview, I talked with Dr. Arnold about how she got into alternative energy during the Carter administration (and got out again during the Reagan administration), what she sees in the P450 enzyme, and how she explains her work to people outside her field. tag:odeo.com,2009-07-15,24823417 Wed, 15 Jul 2009 08:37:33 -0700 no MicrobeWorld's Meet the Scientist Podcast alternative, energy, Design, Science, engineering, biofuel, chemical, systems, evolutionary, Biochemistry, Enzymes, biological, p450, cellulolytic, arnold frances http://www.odeo.com/episodes/24778603-An-important-message-for-Meet-The-Scientist-subscribers The Meet The Scientist (MTS) podcast is moving to a new website. MTS can now be found on MicrobeWorld.org. MicrobeWorld is the home of all the video and audio podcasts produced by The American Society for Microbiology. Besides podcasts, MicrobeWorld is an aggregator of the best microbiology related news, images, videos and resources found on the net. MicrobeWorld.org allows registered users to be editors and/or curators of the site. Any action users take, from clicking on an article, rating a news item, to making a comment, has a direct impact on what appears on the front page. If you are a subscriber to the Meet the Scientist podcast and you find your feed is interrupted, please re-subscribe via iTunes or use this RSS feed: http://feeds.feedburner.com/meetthescientist - in your podcast player of choice. Please be sure to go to MicrobeWorld.org and create a free profile which will allow you to be an active participant in the MicrobeWorld community. We look forward to meeting and cha... The Meet The Scientist (MTS) podcast is moving to a new website. MTS can now be found on MicrobeWorld.org. MicrobeWorld is the home of all the video and audio podcasts produced by The American Society for Microbiology. Besides podcasts, MicrobeWorld is an aggregator of the best microbiology related news, images, videos and resources found on the net. MicrobeWorld.org allows registered users to be editors and/or curators of the site. Any action users take, from clicking on an article, rating a news item, to making a comment, has a direct impact on what appears on the front page. If you are a subscriber to the Meet the Scientist podcast and you find your feed is interrupted, please re-subscribe via iTunes or use this RSS feed: http://feeds.feedburner.com/meetthescientist - in your podcast player of choice. Please be sure to go to MicrobeWorld.org and create a free profile which will allow you to be an active participant in the MicrobeWorld community. We look forward to meeting and chatting with you at MicrobeWorld.org! The Meet The Scientist (MTS) podcast is moving to a new website. MTS can now be found on MicrobeWorld.org. MicrobeWorld is the home of all the video and audio podcasts produced by The American Society for Microbiology. Besides podcasts, MicrobeWorld is an aggregator of the best microbiology related news, images, videos and resources found on the net. MicrobeWorld.org allows registered users to be editors and/or curators of the site. Any action users take, from clicking on an article, rating a news item, to making a comment, has a direct impact on what appears on the front page. If you are a subscriber to the Meet the Scientist podcast and you find your feed is interrupted, please re-subscribe via iTunes or use this RSS feed: http://feeds.feedburner.com/meetthescientist - in your podcast player of choice. Please be sure to go to MicrobeWorld.org and create a free profile which will allow you to be an active participant in the MicrobeWorld community. We look forward to meeting and chatting with you at MicrobeWorld.org! tag:odeo.com,2009-07-10,24778603 Fri, 10 Jul 2009 12:10:10 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24823418-An-important-message-for-Meet-The-Scientist-subscribers The Meet The Scientist (MTS) podcast is moving to a new website. MTS can now be found on MicrobeWorld.org. MicrobeWorld is the home of all the video and audio podcasts produced by The American Society for Microbiology. Besides podcasts, MicrobeWorld is an aggregator of the best microbiology related news, images, videos and resources found on the net. MicrobeWorld.org allows registered users to be editors and/or curators of the site. Any action users take, from clicking on an article, rating a news item, to making a comment, has a direct impact on what appears on the front page.If you are a subscriber to the Meet the Scientist podcast and you find your feed is interrupted, please re-subscribe via iTunes or use this RSS feed: http://feeds.feedburner.com/meetthescientist - in your podcast player of choice.Please be sure to go to MicrobeWorld.org and create a free profile which will allow you to be an active participant in the MicrobeWorld community. We look forward to meeting and chatt... The Meet The Scientist (MTS) podcast is moving to a new website. MTS can now be found on MicrobeWorld.org. MicrobeWorld is the home of all the video and audio podcasts produced by The American Society for Microbiology. Besides podcasts, MicrobeWorld is an aggregator of the best microbiology related news, images, videos and resources found on the net. MicrobeWorld.org allows registered users to be editors and/or curators of the site. Any action users take, from clicking on an article, rating a news item, to making a comment, has a direct impact on what appears on the front page.If you are a subscriber to the Meet the Scientist podcast and you find your feed is interrupted, please re-subscribe via iTunes or use this RSS feed: http://feeds.feedburner.com/meetthescientist - in your podcast player of choice.Please be sure to go to MicrobeWorld.org and create a free profile which will allow you to be an active participant in the MicrobeWorld community. We look forward to meeting and chatting with you at MicrobeWorld.org! The Meet The Scientist (MTS) podcast is moving to a new website. MTS can now be found on MicrobeWorld.org. MicrobeWorld is the home of all the video and audio podcasts produced by The American Society for Microbiology. Besides podcasts, MicrobeWorld is an aggregator of the best microbiology related news, images, videos and resources found on the net. MicrobeWorld.org allows registered users to be editors and/or curators of the site. Any action users take, from clicking on an article, rating a news item, to making a comment, has a direct impact on what appears on the front page.If you are a subscriber to the Meet the Scientist podcast and you find your feed is interrupted, please re-subscribe via iTunes or use this RSS feed: http://feeds.feedburner.com/meetthescientist - in your podcast player of choice.Please be sure to go to MicrobeWorld.org and create a free profile which will allow you to be an active participant in the MicrobeWorld community. We look forward to meeting and chatting with you at MicrobeWorld.org! tag:odeo.com,2009-07-10,24823418 Fri, 10 Jul 2009 11:03:41 -0700 no MicrobeWorld's Meet the Scientist Podcast web, Science, website, moving, scientist, meet, MicrobeWorld http://www.odeo.com/episodes/24744630-MTS29-Christine-Biron-The-Innate-Immune-System Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology. When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate an... Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology. When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate and adaptive immune responses. In this interview, I talked with Dr. Biron about our increasing awareness of the innate immune system, why it’s important to bring microbiologists and immunologists together under one big tent, and why it’s best that a battle between a virus and a host ends not in victory for one and defeat for the other, but in détente. Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology. When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate and adaptive immune responses. In this interview, I talked with Dr. Biron about our increasing awareness of the innate immune system, why it’s important to bring microbiologists and immunologists together under one big tent, and why it’s best that a battle between a virus and a host ends not in victory for one and defeat for the other, but in détente. tag:odeo.com,2009-07-02,24744630 Thu, 02 Jul 2009 06:38:02 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24823419-MTS30-Stanley-Plotkin-The-Past-Present-and-Future-of-Vaccines Stanley Plotkin is Professor Emeritus at the Wistar Institute and the University of Pennsylvania, Philadelphia. A renowned vaccinologist, Dr. Plotkin is, perhaps, best known for developing a highly successful vaccine for rubella back in 1968. We are still using the same vaccine 40 years later. Dr. Plotkin has been honored with the inaugural Maurice Hilleman / Merck Award for his lifetime of dedication to vaccinology. For most people, rubella amounts to a bad rash and a crummy week, but for a fetus, the risks from infection are extremely serious. The rubella virus inhibits tissue growth in infected fetuses, often resulting in profound birth defects collectively referred to as congenital rubella syndrome. Dr. Plotkin developed the rubella vaccine in the wake of a rubella pandemic in 1964, during which he estimates that about 1 in 100 women in his home city of Philadelphia came down with rubella. Nationwide, thousands of babies were born with congenital rubella syndrome in the wake of ... Stanley Plotkin is Professor Emeritus at the Wistar Institute and the University of Pennsylvania, Philadelphia. A renowned vaccinologist, Dr. Plotkin is, perhaps, best known for developing a highly successful vaccine for rubella back in 1968. We are still using the same vaccine 40 years later. Dr. Plotkin has been honored with the inaugural Maurice Hilleman / Merck Award for his lifetime of dedication to vaccinology. For most people, rubella amounts to a bad rash and a crummy week, but for a fetus, the risks from infection are extremely serious. The rubella virus inhibits tissue growth in infected fetuses, often resulting in profound birth defects collectively referred to as congenital rubella syndrome. Dr. Plotkin developed the rubella vaccine in the wake of a rubella pandemic in 1964, during which he estimates that about 1 in 100 women in his home city of Philadelphia came down with rubella. Nationwide, thousands of babies were born with congenital rubella syndrome in the wake of the outbreak. Thanks to the vaccine developed by Dr. Plotkin, rubella has essentially been eradicated in the U.S. and most other developed countries. In many parts of the developing world, efforts are underway to piggy back the rubella vaccine with the measles vaccine to eradicate both of these diseases everywhere else. In this interview, I talked with Dr. Plotkin about the backlash against vaccines for their perceived safety risks, how he would change vaccine policy, and about the rewards of a career in vaccine development. Stanley Plotkin is Professor Emeritus at the Wistar Institute and the University of Pennsylvania, Philadelphia. A renowned vaccinologist, Dr. Plotkin is, perhaps, best known for developing a highly successful vaccine for rubella back in 1968. We are still using the same vaccine 40 years later. Dr. Plotkin has been honored with the inaugural Maurice Hilleman / Merck Award for his lifetime of dedication to vaccinology. For most people, rubella amounts to a bad rash and a crummy week, but for a fetus, the risks from infection are extremely serious. The rubella virus inhibits tissue growth in infected fetuses, often resulting in profound birth defects collectively referred to as congenital rubella syndrome. Dr. Plotkin developed the rubella vaccine in the wake of a rubella pandemic in 1964, during which he estimates that about 1 in 100 women in his home city of Philadelphia came down with rubella. Nationwide, thousands of babies were born with congenital rubella syndrome in the wake of the outbreak. Thanks to the vaccine developed by Dr. Plotkin, rubella has essentially been eradicated in the U.S. and most other developed countries. In many parts of the developing world, efforts are underway to piggy back the rubella vaccine with the measles vaccine to eradicate both of these diseases everywhere else. In this interview, I talked with Dr. Plotkin about the backlash against vaccines for their perceived safety risks, how he would change vaccine policy, and about the rewards of a career in vaccine development. tag:odeo.com,2009-07-01,24823419 Wed, 01 Jul 2009 13:29:08 -0700 no MicrobeWorld's Meet the Scientist Podcast Science, safety, award, rubella, virus, vaccine, Merck, Stanley, plotkin, wistar, hilleman http://www.odeo.com/episodes/24920086-MTS30-Stanley-Plotkin-The-Past-Present-and-Future-of-Vaccines Stanley Plotkin is Professor Emeritus at the Wistar Institute and the University of Pennsylvania, Philadelphia. A renowned vaccinologist, Dr. Plotkin is, perhaps, best known for developing a highly successful vaccine for rubella back in 1968. We are still using the same vaccine 40 years later. Dr. Plotkin has been honored with the inaugural Maurice Hilleman / Merck Award for his lifetime of dedication to vaccinology. For most people, rubella amounts to a bad rash and a crummy week, but for a fetus, the risks from infection are extremely serious. The rubella virus inhibits tissue growth in infected fetuses, often resulting in profound birth defects collectively referred to as congenital rubella syndrome. Dr. Plotkin developed the rubella vaccine in the wake of a rubella pandemic in 1964, during which he estimates that about 1 in 100 women in his home city of Philadelphia came down with rubella. Nationwide, thousands of babies were born with congenital rubella syndrome in the wake of ... Stanley Plotkin is Professor Emeritus at the Wistar Institute and the University of Pennsylvania, Philadelphia. A renowned vaccinologist, Dr. Plotkin is, perhaps, best known for developing a highly successful vaccine for rubella back in 1968. We are still using the same vaccine 40 years later. Dr. Plotkin has been honored with the inaugural Maurice Hilleman / Merck Award for his lifetime of dedication to vaccinology. For most people, rubella amounts to a bad rash and a crummy week, but for a fetus, the risks from infection are extremely serious. The rubella virus inhibits tissue growth in infected fetuses, often resulting in profound birth defects collectively referred to as congenital rubella syndrome. Dr. Plotkin developed the rubella vaccine in the wake of a rubella pandemic in 1964, during which he estimates that about 1 in 100 women in his home city of Philadelphia came down with rubella. Nationwide, thousands of babies were born with congenital rubella syndrome in the wake of the outbreak. Thanks to the vaccine developed by Dr. Plotkin, rubella has essentially been eradicated in the U.S. and most other developed countries. In many parts of the developing world, efforts are underway to piggy back the rubella vaccine with the measles vaccine to eradicate both of these diseases everywhere else. In this interview, I talked with Dr. Plotkin about the backlash against vaccines for their perceived safety risks, how he would change vaccine policy, and about the rewards of a career in vaccine development. Stanley Plotkin is Professor Emeritus at the Wistar Institute and the University of Pennsylvania, Philadelphia. A renowned vaccinologist, Dr. Plotkin is, perhaps, best known for developing a highly successful vaccine for rubella back in 1968. We are still using the same vaccine 40 years later. Dr. Plotkin has been honored with the inaugural Maurice Hilleman / Merck Award for his lifetime of dedication to vaccinology. For most people, rubella amounts to a bad rash and a crummy week, but for a fetus, the risks from infection are extremely serious. The rubella virus inhibits tissue growth in infected fetuses, often resulting in profound birth defects collectively referred to as congenital rubella syndrome. Dr. Plotkin developed the rubella vaccine in the wake of a rubella pandemic in 1964, during which he estimates that about 1 in 100 women in his home city of Philadelphia came down with rubella. Nationwide, thousands of babies were born with congenital rubella syndrome in the wake of the outbreak. Thanks to the vaccine developed by Dr. Plotkin, rubella has essentially been eradicated in the U.S. and most other developed countries. In many parts of the developing world, efforts are underway to piggy back the rubella vaccine with the measles vaccine to eradicate both of these diseases everywhere else. In this interview, I talked with Dr. Plotkin about the backlash against vaccines for their perceived safety risks, how he would change vaccine policy, and about the rewards of a career in vaccine development. tag:odeo.com,2009-07-01,24920086 Wed, 01 Jul 2009 12:10:10 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24744629-MTS30-Stanley-Plotkin-The-Past-Present-and-Future-of-Vaccines Stanley Plotkin is Professor Emeritus at the Wistar Institute and the University of Pennsylvania, Philadelphia. A renowned vaccinologist, Dr. Plotkin is, perhaps, best known for developing a highly successful vaccine for rubella back in 1968. We are still using the same vaccine 40 years later. Dr. Plotkin has been honored with the inaugural Maurice Hilleman / Merck Award for his lifetime of dedication to vaccinology. For most people, rubella amounts to a bad rash and a crummy week, but for a fetus, the risks from infection are extremely serious. The rubella virus inhibits tissue growth in infected fetuses, often resulting in profound birth defects collectively referred to as congenital rubella syndrome. Dr. Plotkin developed the rubella vaccine in the wake of a rubella pandemic in 1964, during which he estimates that about 1 in 100 women in his home city of Philadelphia came down with rubella. Nationwide, thousands of babies were born with congenital rubella syndrome in the wake of ... Stanley Plotkin is Professor Emeritus at the Wistar Institute and the University of Pennsylvania, Philadelphia. A renowned vaccinologist, Dr. Plotkin is, perhaps, best known for developing a highly successful vaccine for rubella back in 1968. We are still using the same vaccine 40 years later. Dr. Plotkin has been honored with the inaugural Maurice Hilleman / Merck Award for his lifetime of dedication to vaccinology. For most people, rubella amounts to a bad rash and a crummy week, but for a fetus, the risks from infection are extremely serious. The rubella virus inhibits tissue growth in infected fetuses, often resulting in profound birth defects collectively referred to as congenital rubella syndrome. Dr. Plotkin developed the rubella vaccine in the wake of a rubella pandemic in 1964, during which he estimates that about 1 in 100 women in his home city of Philadelphia came down with rubella. Nationwide, thousands of babies were born with congenital rubella syndrome in the wake of the outbreak. Thanks to the vaccine developed by Dr. Plotkin, rubella has essentially been eradicated in the U.S. and most other developed countries. In many parts of the developing world, efforts are underway to piggy back the rubella vaccine with the measles vaccine to eradicate both of these diseases everywhere else. In this interview, I talked with Dr. Plotkin about the backlash against vaccines for their perceived safety risks, how he would change vaccine policy, and about the rewards of a career in vaccine development. Stanley Plotkin is Professor Emeritus at the Wistar Institute and the University of Pennsylvania, Philadelphia. A renowned vaccinologist, Dr. Plotkin is, perhaps, best known for developing a highly successful vaccine for rubella back in 1968. We are still using the same vaccine 40 years later. Dr. Plotkin has been honored with the inaugural Maurice Hilleman / Merck Award for his lifetime of dedication to vaccinology. For most people, rubella amounts to a bad rash and a crummy week, but for a fetus, the risks from infection are extremely serious. The rubella virus inhibits tissue growth in infected fetuses, often resulting in profound birth defects collectively referred to as congenital rubella syndrome. Dr. Plotkin developed the rubella vaccine in the wake of a rubella pandemic in 1964, during which he estimates that about 1 in 100 women in his home city of Philadelphia came down with rubella. Nationwide, thousands of babies were born with congenital rubella syndrome in the wake of the outbreak. Thanks to the vaccine developed by Dr. Plotkin, rubella has essentially been eradicated in the U.S. and most other developed countries. In many parts of the developing world, efforts are underway to piggy back the rubella vaccine with the measles vaccine to eradicate both of these diseases everywhere else. In this interview, I talked with Dr. Plotkin about the backlash against vaccines for their perceived safety risks, how he would change vaccine policy, and about the rewards of a career in vaccine development. tag:odeo.com,2009-07-01,24744629 Wed, 01 Jul 2009 12:10:10 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24724968-MTS29-Christine-Biron-The-Innate-Immune-System Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology. When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate an... Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology. When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate and adaptive immune responses. In this interview, I talked with Dr. Biron about our increasing awareness of the innate immune system, why it’s important to bring microbiologists and immunologists together under one big tent, and why it’s best that a battle between a virus and a host ends not in victory for one and defeat for the other, but in détente. Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology. When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate and adaptive immune responses. In this interview, I talked with Dr. Biron about our increasing awareness of the innate immune system, why it’s important to bring microbiologists and immunologists together under one big tent, and why it’s best that a battle between a virus and a host ends not in victory for one and defeat for the other, but in détente. tag:odeo.com,2009-06-18,24724968 Thu, 18 Jun 2009 09:57:47 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24823420-MTS29-Christine-Biron-The-Innate-Immune-System Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology.When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing ... Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology.When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate and adaptive immune responses.In this interview, I talked with Dr. Biron about our increasing awareness of the innate immune system, why it’s important to bring microbiologists and immunologists together under one big tent, and why it’s best that a battle between a virus and a host ends not in victory for one and defeat for the other, but in détente. Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology.When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate and adaptive immune responses.In this interview, I talked with Dr. Biron about our increasing awareness of the innate immune system, why it’s important to bring microbiologists and immunologists together under one big tent, and why it’s best that a battle between a virus and a host ends not in victory for one and defeat for the other, but in détente. tag:odeo.com,2009-06-18,24823420 Thu, 18 Jun 2009 07:19:43 -0700 no MicrobeWorld's Meet the Scientist Podcast Science, microbiology, System, molecular, Immunology, immune, pathogens, biron, interferons, innate http://www.odeo.com/episodes/24961938-MTS29-Christine-Biron-The-Innate-Immune-System Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology. When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate an... Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology. When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate and adaptive immune responses. In this interview, I talked with Dr. Biron about our increasing awareness of the innate immune system, why it’s important to bring microbiologists and immunologists together under one big tent, and why it’s best that a battle between a virus and a host ends not in victory for one and defeat for the other, but in détente. Christine Biron is the chair of the Department of Molecular Microbiology and Immunology at Brown University in Providence, and she focuses her research program on the mechanisms of the innate immune system – the body’s system of non-specific munitions for fighting off pathogens. Dr. Biron is also a newly elected fellow of the American Academy of Microbiology. When a pathogen gets on or in your body, your innate immune system is on the front lines, working against the pathogen is a non-specific manner. In research, the innate immune system got short shrift for a long time, and only in the last 10 or 20 years has the field picked up momentum. Dr. Biron says back when she was in graduate school “the innate immune system wasn’t thought to be very cool”, but she says the field is fast-moving today, in part because of some major discoveries involving Type-1 interferons, natural killer cells, and an increased appreciation of a wider range of antigen processing cells that link the innate and adaptive immune responses. In this interview, I talked with Dr. Biron about our increasing awareness of the innate immune system, why it’s important to bring microbiologists and immunologists together under one big tent, and why it’s best that a battle between a virus and a host ends not in victory for one and defeat for the other, but in détente. tag:odeo.com,2009-06-18,24961938 Thu, 18 Jun 2009 06:24:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24678600-MTS10-Anthony-Maurelli-Black-Holes-and-Antivirulence-Genes Tony Maurelli is a professor of microbiology and immunology in the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. Dr. Maurelli’s major research interest lies in the genetics of bacterial pathogenesis – the genetic nuts and bolts of how bacteria infect humans and make us sick. Dr. Maurelli’s work has uncovered “antivirulence genes” in Shigella flexneri, a major cause of dysentery and food borne illness. This is an interesting concept: antivirulence genes undermine pathogenicity, so they must be broken or dropped from the genome for a bacterium to take good advantage of a host and cause disease. These genes are a hindrance, so to become an effective pathogen, Shigella must stop using them. In this interview, Dr. Merry Buckley talks with Dr. Maurelli about antivirulence genes, whether the naming system for bacteria should be fixed, and his favorite microbe. Tony Maurelli is a professor of microbiology and immunology in the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. Dr. Maurelli’s major research interest lies in the genetics of bacterial pathogenesis – the genetic nuts and bolts of how bacteria infect humans and make us sick. Dr. Maurelli’s work has uncovered “antivirulence genes” in Shigella flexneri, a major cause of dysentery and food borne illness. This is an interesting concept: antivirulence genes undermine pathogenicity, so they must be broken or dropped from the genome for a bacterium to take good advantage of a host and cause disease. These genes are a hindrance, so to become an effective pathogen, Shigella must stop using them. In this interview, Dr. Merry Buckley talks with Dr. Maurelli about antivirulence genes, whether the naming system for bacteria should be fixed, and his favorite microbe. Tony Maurelli is a professor of microbiology and immunology in the F. Edward Hébert School of Medicine at the Uniformed Services University of the Health Sciences in Bethesda, Maryland. Dr. Maurelli’s major research interest lies in the genetics of bacterial pathogenesis – the genetic nuts and bolts of how bacteria infect humans and make us sick. Dr. Maurelli’s work has uncovered “antivirulence genes” in Shigella flexneri, a major cause of dysentery and food borne illness. This is an interesting concept: antivirulence genes undermine pathogenicity, so they must be broken or dropped from the genome for a bacterium to take good advantage of a host and cause disease. These genes are a hindrance, so to become an effective pathogen, Shigella must stop using them. In this interview, Dr. Merry Buckley talks with Dr. Maurelli about antivirulence genes, whether the naming system for bacteria should be fixed, and his favorite microbe. tag:odeo.com,2009-06-09,24678600 Tue, 09 Jun 2009 14:35:49 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24678580-MTS28-Joseph-DeRisi-New-Tech-Approaches-to-Infectious-Disease Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career. Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies a... Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career. Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies and control measures to help both captive birds and birds in the wild can’t be far behind. In this interview, I asked Dr. DeRisi whether he’s interested in putting the microarray approach to virus discovery to work in uncovering the causes of some human illnesses, especially those diseases we suspect might be spread by viruses, but for which we’ve never found a virus responsible. He has some very interesting ideas for where to start. We also talked about his work on identifying the SARS virus, and a new approach in the ongoing fight against malaria. ID3 Podcast Image Provided by James Gathany Courtesy of the CDC. Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career. Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies and control measures to help both captive birds and birds in the wild can’t be far behind. In this interview, I asked Dr. DeRisi whether he’s interested in putting the microarray approach to virus discovery to work in uncovering the causes of some human illnesses, especially those diseases we suspect might be spread by viruses, but for which we’ve never found a virus responsible. He has some very interesting ideas for where to start. We also talked about his work on identifying the SARS virus, and a new approach in the ongoing fight against malaria. ID3 Podcast Image Provided by James Gathany Courtesy of the CDC. tag:odeo.com,2009-06-09,24678580 Tue, 09 Jun 2009 14:35:43 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24640927-MTS28-Joseph-DeRisi-New-Tech-Approaches-to-Infectious-Disease Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career. Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies a... Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career. Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies and control measures to help both captive birds and birds in the wild can’t be far behind. In this interview, I asked Dr. DeRisi whether he’s interested in putting the microarray approach to virus discovery to work in uncovering the causes of some human illnesses, especially those diseases we suspect might be spread by viruses, but for which we’ve never found a virus responsible. He has some very interesting ideas for where to start. We also talked about his work on identifying the SARS virus, and a new approach in the ongoing fight against malaria. ID3 Podcast Image Provided by James Gathany Courtesy of the CDC. Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career. Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies and control measures to help both captive birds and birds in the wild can’t be far behind. In this interview, I asked Dr. DeRisi whether he’s interested in putting the microarray approach to virus discovery to work in uncovering the causes of some human illnesses, especially those diseases we suspect might be spread by viruses, but for which we’ve never found a virus responsible. He has some very interesting ideas for where to start. We also talked about his work on identifying the SARS virus, and a new approach in the ongoing fight against malaria. ID3 Podcast Image Provided by James Gathany Courtesy of the CDC. tag:odeo.com,2009-06-02,24640927 Tue, 02 Jun 2009 11:57:32 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24823421-MTS28-Joseph-DeRisi-New-Tech-Approaches-to-Infectious-Disease Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career.Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its ge... Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career.Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies and control measures to help both captive birds and birds in the wild can’t be far behind.In this interview, I asked Dr. DeRisi whether he’s interested in putting the microarray approach to virus discovery to work in uncovering the causes of some human illnesses, especially those diseases we suspect might be spread by viruses, but for which we’ve never found a virus responsible. He has some very interesting ideas for where to start. We also talked about his work on identifying the SARS virus, and a new approach in the ongoing fight against malaria.ID3 Podcast Image Provided by James Gathany Courtesy of the CDC. Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career.Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies and control measures to help both captive birds and birds in the wild can’t be far behind.In this interview, I asked Dr. DeRisi whether he’s interested in putting the microarray approach to virus discovery to work in uncovering the causes of some human illnesses, especially those diseases we suspect might be spread by viruses, but for which we’ve never found a virus responsible. He has some very interesting ideas for where to start. We also talked about his work on identifying the SARS virus, and a new approach in the ongoing fight against malaria.ID3 Podcast Image Provided by James Gathany Courtesy of the CDC. tag:odeo.com,2009-06-02,24823421 Tue, 02 Jun 2009 09:27:07 -0700 no MicrobeWorld's Meet the Scientist Podcast Science, microbiology, viral, genome, disease, discovery, sequence, Immunology, Eli Lilly, Malaria, Biochemistry, SARS, pathogen, parrots, avian bornavirus, derisi, microarray, proventricular, dilatation http://www.odeo.com/episodes/24961939-MTS28-Joseph-DeRisi-New-Tech-Approaches-to-Infectious-Disease Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career. Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies a... Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career. Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies and control measures to help both captive birds and birds in the wild can’t be far behind. In this interview, I asked Dr. DeRisi whether he’s interested in putting the microarray approach to virus discovery to work in uncovering the causes of some human illnesses, especially those diseases we suspect might be spread by viruses, but for which we’ve never found a virus responsible. He has some very interesting ideas for where to start. We also talked about his work on identifying the SARS virus, and a new approach in the ongoing fight against malaria. ID3 Podcast Image Provided by James Gathany Courtesy of the CDC. Joseph DeRisi is a Professor of Biochemistry and Biophysics at the University of California, San Francisco and a Howard Hughes Medical Institute Investigator. His research focuses on two distinct areas: malaria and new viral pathogen discovery. Dr. DeRisi is this year’s recipient of the Eli Lilly and Company Research Award, granted in recognition of fundamental research of unusual merit in microbiology or immunology by an individual on the threshold of his or her career. Discovering new viral pathogens seems like exciting work, and DeRisi has lots of ideas for prospecting. In one recent success with their viral microarray, his group recently helped identify the virus responsible for a devastating disease among rare parrots and other birds: proventricular dilatation disease, or PDD, has been recognized for 30 years, but veterinarians didn’t know the cause or how to control it. Now that DeRisi’s group has pinpointed Avian Bornavirus as the culprit and sequenced its genome, therapies and control measures to help both captive birds and birds in the wild can’t be far behind. In this interview, I asked Dr. DeRisi whether he’s interested in putting the microarray approach to virus discovery to work in uncovering the causes of some human illnesses, especially those diseases we suspect might be spread by viruses, but for which we’ve never found a virus responsible. He has some very interesting ideas for where to start. We also talked about his work on identifying the SARS virus, and a new approach in the ongoing fight against malaria. ID3 Podcast Image Provided by James Gathany Courtesy of the CDC. tag:odeo.com,2009-06-02,24961939 Tue, 02 Jun 2009 08:34:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24823422-MTS27-Melanie-Cushion-Pneumocystis-carinii Melanie Cushion holds down two jobs: she’s a research career scientist at the Veterans Administration Medical Center in Cincinnati, Ohio, and she’s also professor and associate chair for research in the department of internal medicine at the University of Cincinnati College of Medicine. Dr. Cushion focuses her research on the fungus, Pneumocystis carinii, which is a harmless commensal for most people, but a deadly pathogen for others. Pneumocystis carinii was shrouded in obscurity for many years until its fifteen minutes in the spotlight came in the 80’s, when, unfortunately, an outbreak of Pneumocystis pneumonia prefigured the AIDS epidemic. Large numbers of previously healthy homosexual men in California became deathly ill with Pneumocystis pneumonia, and doctors knew something unusual (later found to be HIV) was going on. Dr. Cushion says Pneumocystis pneumonia is an opportunistic infection: it strikes individuals with immune systems too weak to fend it off. Thi... Melanie Cushion holds down two jobs: she’s a research career scientist at the Veterans Administration Medical Center in Cincinnati, Ohio, and she’s also professor and associate chair for research in the department of internal medicine at the University of Cincinnati College of Medicine. Dr. Cushion focuses her research on the fungus, Pneumocystis carinii, which is a harmless commensal for most people, but a deadly pathogen for others. Pneumocystis carinii was shrouded in obscurity for many years until its fifteen minutes in the spotlight came in the 80’s, when, unfortunately, an outbreak of Pneumocystis pneumonia prefigured the AIDS epidemic. Large numbers of previously healthy homosexual men in California became deathly ill with Pneumocystis pneumonia, and doctors knew something unusual (later found to be HIV) was going on. Dr. Cushion says Pneumocystis pneumonia is an opportunistic infection: it strikes individuals with immune systems too weak to fend it off. This explains why it was – and still is – a well-known sign that the patient is stricken with an active HIV infection or some other immune-suppressing disorder. Dr. Cushion heads up the Pneumocystis genome project and she’s also looking into a new line of drugs called glucan synthase inhibitors, which have a profound effect on Pneumocystis’s life cycle and may offer new insights into managing the pathogen.In this interview, I talked with Dr. Cushion about some of the more surprising results to come out of her genomics work, why Pneumocystis is a tough nut to crack in the laboratory, and about why she’s not giving her young investigator award back to the Society of Protozoologists any time soon. Melanie Cushion holds down two jobs: she’s a research career scientist at the Veterans Administration Medical Center in Cincinnati, Ohio, and she’s also professor and associate chair for research in the department of internal medicine at the University of Cincinnati College of Medicine. Dr. Cushion focuses her research on the fungus, Pneumocystis carinii, which is a harmless commensal for most people, but a deadly pathogen for others. Pneumocystis carinii was shrouded in obscurity for many years until its fifteen minutes in the spotlight came in the 80’s, when, unfortunately, an outbreak of Pneumocystis pneumonia prefigured the AIDS epidemic. Large numbers of previously healthy homosexual men in California became deathly ill with Pneumocystis pneumonia, and doctors knew something unusual (later found to be HIV) was going on. Dr. Cushion says Pneumocystis pneumonia is an opportunistic infection: it strikes individuals with immune systems too weak to fend it off. This explains why it was – and still is – a well-known sign that the patient is stricken with an active HIV infection or some other immune-suppressing disorder. Dr. Cushion heads up the Pneumocystis genome project and she’s also looking into a new line of drugs called glucan synthase inhibitors, which have a profound effect on Pneumocystis’s life cycle and may offer new insights into managing the pathogen.In this interview, I talked with Dr. Cushion about some of the more surprising results to come out of her genomics work, why Pneumocystis is a tough nut to crack in the laboratory, and about why she’s not giving her young investigator award back to the Society of Protozoologists any time soon. tag:odeo.com,2009-05-14,24823422 Thu, 14 May 2009 12:45:16 -0700 no MicrobeWorld's Meet the Scientist Podcast HIV, Science, genome, aids, fungus, pneumonia, protozoologist, carinii, melanie cushion, glucan, pneumocystis, synthase, commensal http://www.odeo.com/episodes/24920089-MTS27-Melanie-Cushion-Pneumocystis-carinii Melanie Cushion holds down two jobs: she’s a research career scientist at the Veterans Administration Medical Center in Cincinnati, Ohio, and she’s also professor and associate chair for research in the department of internal medicine at the University of Cincinnati College of Medicine. Dr. Cushion focuses her research on the fungus, Pneumocystis carinii, which is a harmless commensal for most people, but a deadly pathogen for others. Pneumocystis carinii was shrouded in obscurity for many years until its fifteen minutes in the spotlight came in the 80’s, when, unfortunately, an outbreak of Pneumocystis pneumonia prefigured the AIDS epidemic. Large numbers of previously healthy homosexual men in California became deathly ill with Pneumocystis pneumonia, and doctors knew something unusual (later found to be HIV) was going on. Dr. Cushion says Pneumocystis pneumonia is an opportunistic infection: it strikes individuals with immune systems too weak to fend it off. This explains why it ... Melanie Cushion holds down two jobs: she’s a research career scientist at the Veterans Administration Medical Center in Cincinnati, Ohio, and she’s also professor and associate chair for research in the department of internal medicine at the University of Cincinnati College of Medicine. Dr. Cushion focuses her research on the fungus, Pneumocystis carinii, which is a harmless commensal for most people, but a deadly pathogen for others. Pneumocystis carinii was shrouded in obscurity for many years until its fifteen minutes in the spotlight came in the 80’s, when, unfortunately, an outbreak of Pneumocystis pneumonia prefigured the AIDS epidemic. Large numbers of previously healthy homosexual men in California became deathly ill with Pneumocystis pneumonia, and doctors knew something unusual (later found to be HIV) was going on. Dr. Cushion says Pneumocystis pneumonia is an opportunistic infection: it strikes individuals with immune systems too weak to fend it off. This explains why it was – and still is – a well-known sign that the patient is stricken with an active HIV infection or some other immune-suppressing disorder. Dr. Cushion heads up the Pneumocystis genome project and she’s also looking into a new line of drugs called glucan synthase inhibitors, which have a profound effect on Pneumocystis’s life cycle and may offer new insights into managing the pathogen. In this interview, I talked with Dr. Cushion about some of the more surprising results to come out of her genomics work, why Pneumocystis is a tough nut to crack in the laboratory, and about why she’s not giving her young investigator award back to the Society of Protozoologists any time soon. Melanie Cushion holds down two jobs: she’s a research career scientist at the Veterans Administration Medical Center in Cincinnati, Ohio, and she’s also professor and associate chair for research in the department of internal medicine at the University of Cincinnati College of Medicine. Dr. Cushion focuses her research on the fungus, Pneumocystis carinii, which is a harmless commensal for most people, but a deadly pathogen for others. Pneumocystis carinii was shrouded in obscurity for many years until its fifteen minutes in the spotlight came in the 80’s, when, unfortunately, an outbreak of Pneumocystis pneumonia prefigured the AIDS epidemic. Large numbers of previously healthy homosexual men in California became deathly ill with Pneumocystis pneumonia, and doctors knew something unusual (later found to be HIV) was going on. Dr. Cushion says Pneumocystis pneumonia is an opportunistic infection: it strikes individuals with immune systems too weak to fend it off. This explains why it was – and still is – a well-known sign that the patient is stricken with an active HIV infection or some other immune-suppressing disorder. Dr. Cushion heads up the Pneumocystis genome project and she’s also looking into a new line of drugs called glucan synthase inhibitors, which have a profound effect on Pneumocystis’s life cycle and may offer new insights into managing the pathogen. In this interview, I talked with Dr. Cushion about some of the more surprising results to come out of her genomics work, why Pneumocystis is a tough nut to crack in the laboratory, and about why she’s not giving her young investigator award back to the Society of Protozoologists any time soon. tag:odeo.com,2009-05-14,24920089 Thu, 14 May 2009 11:34:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24558159-MTS27-Melanie-Cushion-Pneumocystis-carinii Melanie Cushion holds down two jobs: she’s a research career scientist at the Veterans Administration Medical Center in Cincinnati, Ohio, and she’s also professor and associate chair for research in the department of internal medicine at the University of Cincinnati College of Medicine. Dr. Cushion focuses her research on the fungus, Pneumocystis carinii, which is a harmless commensal for most people, but a deadly pathogen for others. Pneumocystis carinii was shrouded in obscurity for many years until its fifteen minutes in the spotlight came in the 80’s, when, unfortunately, an outbreak of Pneumocystis pneumonia prefigured the AIDS epidemic. Large numbers of previously healthy homosexual men in California became deathly ill with Pneumocystis pneumonia, and doctors knew something unusual (later found to be HIV) was going on. Dr. Cushion says Pneumocystis pneumonia is an opportunistic infection: it strikes individuals with immune systems too weak to fend it off. This explains why it ... Melanie Cushion holds down two jobs: she’s a research career scientist at the Veterans Administration Medical Center in Cincinnati, Ohio, and she’s also professor and associate chair for research in the department of internal medicine at the University of Cincinnati College of Medicine. Dr. Cushion focuses her research on the fungus, Pneumocystis carinii, which is a harmless commensal for most people, but a deadly pathogen for others. Pneumocystis carinii was shrouded in obscurity for many years until its fifteen minutes in the spotlight came in the 80’s, when, unfortunately, an outbreak of Pneumocystis pneumonia prefigured the AIDS epidemic. Large numbers of previously healthy homosexual men in California became deathly ill with Pneumocystis pneumonia, and doctors knew something unusual (later found to be HIV) was going on. Dr. Cushion says Pneumocystis pneumonia is an opportunistic infection: it strikes individuals with immune systems too weak to fend it off. This explains why it was – and still is – a well-known sign that the patient is stricken with an active HIV infection or some other immune-suppressing disorder. Dr. Cushion heads up the Pneumocystis genome project and she’s also looking into a new line of drugs called glucan synthase inhibitors, which have a profound effect on Pneumocystis’s life cycle and may offer new insights into managing the pathogen. In this interview, I talked with Dr. Cushion about some of the more surprising results to come out of her genomics work, why Pneumocystis is a tough nut to crack in the laboratory, and about why she’s not giving her young investigator award back to the Society of Protozoologists any time soon. Melanie Cushion holds down two jobs: she’s a research career scientist at the Veterans Administration Medical Center in Cincinnati, Ohio, and she’s also professor and associate chair for research in the department of internal medicine at the University of Cincinnati College of Medicine. Dr. Cushion focuses her research on the fungus, Pneumocystis carinii, which is a harmless commensal for most people, but a deadly pathogen for others. Pneumocystis carinii was shrouded in obscurity for many years until its fifteen minutes in the spotlight came in the 80’s, when, unfortunately, an outbreak of Pneumocystis pneumonia prefigured the AIDS epidemic. Large numbers of previously healthy homosexual men in California became deathly ill with Pneumocystis pneumonia, and doctors knew something unusual (later found to be HIV) was going on. Dr. Cushion says Pneumocystis pneumonia is an opportunistic infection: it strikes individuals with immune systems too weak to fend it off. This explains why it was – and still is – a well-known sign that the patient is stricken with an active HIV infection or some other immune-suppressing disorder. Dr. Cushion heads up the Pneumocystis genome project and she’s also looking into a new line of drugs called glucan synthase inhibitors, which have a profound effect on Pneumocystis’s life cycle and may offer new insights into managing the pathogen. In this interview, I talked with Dr. Cushion about some of the more surprising results to come out of her genomics work, why Pneumocystis is a tough nut to crack in the laboratory, and about why she’s not giving her young investigator award back to the Society of Protozoologists any time soon. tag:odeo.com,2009-05-14,24558159 Thu, 14 May 2009 11:34:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24678581-MTS27-Melanie-Cushion-Pneumocystis-carinii Melanie Cushion holds down two jobs: she’s a research career scientist at the Veterans Administration Medical Center in Cincinnati, Ohio, and she’s also professor and associate chair for research in the department of internal medicine at the University of Cincinnati College of Medicine. Dr. Cushion focuses her research on the fungus, Pneumocystis carinii, which is a harmless commensal for most people, but a deadly pathogen for others. Pneumocystis carinii was shrouded in obscurity for many years until its fifteen minutes in the spotlight came in the 80’s, when, unfortunately, an outbreak of Pneumocystis pneumonia prefigured the AIDS epidemic. Large numbers of previously healthy homosexual men in California became deathly ill with Pneumocystis pneumonia, and doctors knew something unusual (later found to be HIV) was going on. Dr. Cushion says Pneumocystis pneumonia is an opportunistic infection: it strikes individuals with immune systems too weak to fend it off. This explains why it ... Melanie Cushion holds down two jobs: she’s a research career scientist at the Veterans Administration Medical Center in Cincinnati, Ohio, and she’s also professor and associate chair for research in the department of internal medicine at the University of Cincinnati College of Medicine. Dr. Cushion focuses her research on the fungus, Pneumocystis carinii, which is a harmless commensal for most people, but a deadly pathogen for others. Pneumocystis carinii was shrouded in obscurity for many years until its fifteen minutes in the spotlight came in the 80’s, when, unfortunately, an outbreak of Pneumocystis pneumonia prefigured the AIDS epidemic. Large numbers of previously healthy homosexual men in California became deathly ill with Pneumocystis pneumonia, and doctors knew something unusual (later found to be HIV) was going on. Dr. Cushion says Pneumocystis pneumonia is an opportunistic infection: it strikes individuals with immune systems too weak to fend it off. This explains why it was – and still is – a well-known sign that the patient is stricken with an active HIV infection or some other immune-suppressing disorder. Dr. Cushion heads up the Pneumocystis genome project and she’s also looking into a new line of drugs called glucan synthase inhibitors, which have a profound effect on Pneumocystis’s life cycle and may offer new insights into managing the pathogen. In this interview, I talked with Dr. Cushion about some of the more surprising results to come out of her genomics work, why Pneumocystis is a tough nut to crack in the laboratory, and about why she’s not giving her young investigator award back to the Society of Protozoologists any time soon. Melanie Cushion holds down two jobs: she’s a research career scientist at the Veterans Administration Medical Center in Cincinnati, Ohio, and she’s also professor and associate chair for research in the department of internal medicine at the University of Cincinnati College of Medicine. Dr. Cushion focuses her research on the fungus, Pneumocystis carinii, which is a harmless commensal for most people, but a deadly pathogen for others. Pneumocystis carinii was shrouded in obscurity for many years until its fifteen minutes in the spotlight came in the 80’s, when, unfortunately, an outbreak of Pneumocystis pneumonia prefigured the AIDS epidemic. Large numbers of previously healthy homosexual men in California became deathly ill with Pneumocystis pneumonia, and doctors knew something unusual (later found to be HIV) was going on. Dr. Cushion says Pneumocystis pneumonia is an opportunistic infection: it strikes individuals with immune systems too weak to fend it off. This explains why it was – and still is – a well-known sign that the patient is stricken with an active HIV infection or some other immune-suppressing disorder. Dr. Cushion heads up the Pneumocystis genome project and she’s also looking into a new line of drugs called glucan synthase inhibitors, which have a profound effect on Pneumocystis’s life cycle and may offer new insights into managing the pathogen. In this interview, I talked with Dr. Cushion about some of the more surprising results to come out of her genomics work, why Pneumocystis is a tough nut to crack in the laboratory, and about why she’s not giving her young investigator award back to the Society of Protozoologists any time soon. tag:odeo.com,2009-05-14,24678581 Thu, 14 May 2009 11:34:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24920090-MTS26-Ian-Orme-Tuberculosis Ian Orme is a professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, and his research focuses on the immune response to tuberculosis (TB) — a bacterial disease that most often infects the lungs. He’s speaking at the American Society for Microbiology’s upcoming meeting on Continuing Undergraduate Education (ASMCUE). In the U.S., TB seems like a thing of the past. Here, public health measures and medical care have all but wiped out the threat from this infection. But worldwide, the WHO says there were 9.2 million new TB cases in 2006 alone, and each person with TB infects an average of 10 to 15 people with the TB bacterium every year. These are just some of the reasons Dr. Orme is delivering a talked titled “Tuberculosis: Why Now Is a Good Time to Leave the Planet” at ASMCUE. He admits leaving the planet isn’t a practical suggestion, but he wants to raise awareness of the disease and he’s not afraid to stir the pot a little. Orme and his g... Ian Orme is a professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, and his research focuses on the immune response to tuberculosis (TB) — a bacterial disease that most often infects the lungs. He’s speaking at the American Society for Microbiology’s upcoming meeting on Continuing Undergraduate Education (ASMCUE). In the U.S., TB seems like a thing of the past. Here, public health measures and medical care have all but wiped out the threat from this infection. But worldwide, the WHO says there were 9.2 million new TB cases in 2006 alone, and each person with TB infects an average of 10 to 15 people with the TB bacterium every year. These are just some of the reasons Dr. Orme is delivering a talked titled “Tuberculosis: Why Now Is a Good Time to Leave the Planet” at ASMCUE. He admits leaving the planet isn’t a practical suggestion, but he wants to raise awareness of the disease and he’s not afraid to stir the pot a little. Orme and his group not only study the immune responses to TB bacteria, they’re also following a number of different avenues for developing new vaccines and improving the existing vaccine, BCG (bacille Calmette-Guérin). In this interview, I talked with Dr. Orme about his vaccine work, why he thinks latent TB bacteria aren’t really latent, and how he sometimes feels like the wild-haired radical, cat-calling from the corner of the lecture hall. Ian Orme is a professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, and his research focuses on the immune response to tuberculosis (TB) — a bacterial disease that most often infects the lungs. He’s speaking at the American Society for Microbiology’s upcoming meeting on Continuing Undergraduate Education (ASMCUE). In the U.S., TB seems like a thing of the past. Here, public health measures and medical care have all but wiped out the threat from this infection. But worldwide, the WHO says there were 9.2 million new TB cases in 2006 alone, and each person with TB infects an average of 10 to 15 people with the TB bacterium every year. These are just some of the reasons Dr. Orme is delivering a talked titled “Tuberculosis: Why Now Is a Good Time to Leave the Planet” at ASMCUE. He admits leaving the planet isn’t a practical suggestion, but he wants to raise awareness of the disease and he’s not afraid to stir the pot a little. Orme and his group not only study the immune responses to TB bacteria, they’re also following a number of different avenues for developing new vaccines and improving the existing vaccine, BCG (bacille Calmette-Guérin). In this interview, I talked with Dr. Orme about his vaccine work, why he thinks latent TB bacteria aren’t really latent, and how he sometimes feels like the wild-haired radical, cat-calling from the corner of the lecture hall. tag:odeo.com,2009-05-07,24920090 Thu, 07 May 2009 11:34:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24558160-MTS26-Ian-Orme-Tuberculosis Ian Orme is a professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, and his research focuses on the immune response to tuberculosis (TB) — a bacterial disease that most often infects the lungs. He’s speaking at the American Society for Microbiology’s upcoming meeting on Continuing Undergraduate Education (ASMCUE). In the U.S., TB seems like a thing of the past. Here, public health measures and medical care have all but wiped out the threat from this infection. But worldwide, the WHO says there were 9.2 million new TB cases in 2006 alone, and each person with TB infects an average of 10 to 15 people with the TB bacterium every year. These are just some of the reasons Dr. Orme is delivering a talked titled “Tuberculosis: Why Now Is a Good Time to Leave the Planet” at ASMCUE. He admits leaving the planet isn’t a practical suggestion, but he wants to raise awareness of the disease and he’s not afraid to stir the pot a little. Orme and his g... Ian Orme is a professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, and his research focuses on the immune response to tuberculosis (TB) — a bacterial disease that most often infects the lungs. He’s speaking at the American Society for Microbiology’s upcoming meeting on Continuing Undergraduate Education (ASMCUE). In the U.S., TB seems like a thing of the past. Here, public health measures and medical care have all but wiped out the threat from this infection. But worldwide, the WHO says there were 9.2 million new TB cases in 2006 alone, and each person with TB infects an average of 10 to 15 people with the TB bacterium every year. These are just some of the reasons Dr. Orme is delivering a talked titled “Tuberculosis: Why Now Is a Good Time to Leave the Planet” at ASMCUE. He admits leaving the planet isn’t a practical suggestion, but he wants to raise awareness of the disease and he’s not afraid to stir the pot a little. Orme and his group not only study the immune responses to TB bacteria, they’re also following a number of different avenues for developing new vaccines and improving the existing vaccine, BCG (bacille Calmette-Guérin). In this interview, I talked with Dr. Orme about his vaccine work, why he thinks latent TB bacteria aren’t really latent, and how he sometimes feels like the wild-haired radical, cat-calling from the corner of the lecture hall. Ian Orme is a professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, and his research focuses on the immune response to tuberculosis (TB) — a bacterial disease that most often infects the lungs. He’s speaking at the American Society for Microbiology’s upcoming meeting on Continuing Undergraduate Education (ASMCUE). In the U.S., TB seems like a thing of the past. Here, public health measures and medical care have all but wiped out the threat from this infection. But worldwide, the WHO says there were 9.2 million new TB cases in 2006 alone, and each person with TB infects an average of 10 to 15 people with the TB bacterium every year. These are just some of the reasons Dr. Orme is delivering a talked titled “Tuberculosis: Why Now Is a Good Time to Leave the Planet” at ASMCUE. He admits leaving the planet isn’t a practical suggestion, but he wants to raise awareness of the disease and he’s not afraid to stir the pot a little. Orme and his group not only study the immune responses to TB bacteria, they’re also following a number of different avenues for developing new vaccines and improving the existing vaccine, BCG (bacille Calmette-Guérin). In this interview, I talked with Dr. Orme about his vaccine work, why he thinks latent TB bacteria aren’t really latent, and how he sometimes feels like the wild-haired radical, cat-calling from the corner of the lecture hall. tag:odeo.com,2009-05-07,24558160 Thu, 07 May 2009 11:34:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24678582-MTS26-Ian-Orme-Tuberculosis Ian Orme is a professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, and his research focuses on the immune response to tuberculosis (TB) — a bacterial disease that most often infects the lungs. He’s speaking at the American Society for Microbiology’s upcoming meeting on Continuing Undergraduate Education (ASMCUE). In the U.S., TB seems like a thing of the past. Here, public health measures and medical care have all but wiped out the threat from this infection. But worldwide, the WHO says there were 9.2 million new TB cases in 2006 alone, and each person with TB infects an average of 10 to 15 people with the TB bacterium every year. These are just some of the reasons Dr. Orme is delivering a talked titled “Tuberculosis: Why Now Is a Good Time to Leave the Planet” at ASMCUE. He admits leaving the planet isn’t a practical suggestion, but he wants to raise awareness of the disease and he’s not afraid to stir the pot a little. Orme and his g... Ian Orme is a professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, and his research focuses on the immune response to tuberculosis (TB) — a bacterial disease that most often infects the lungs. He’s speaking at the American Society for Microbiology’s upcoming meeting on Continuing Undergraduate Education (ASMCUE). In the U.S., TB seems like a thing of the past. Here, public health measures and medical care have all but wiped out the threat from this infection. But worldwide, the WHO says there were 9.2 million new TB cases in 2006 alone, and each person with TB infects an average of 10 to 15 people with the TB bacterium every year. These are just some of the reasons Dr. Orme is delivering a talked titled “Tuberculosis: Why Now Is a Good Time to Leave the Planet” at ASMCUE. He admits leaving the planet isn’t a practical suggestion, but he wants to raise awareness of the disease and he’s not afraid to stir the pot a little. Orme and his group not only study the immune responses to TB bacteria, they’re also following a number of different avenues for developing new vaccines and improving the existing vaccine, BCG (bacille Calmette-Guérin). In this interview, I talked with Dr. Orme about his vaccine work, why he thinks latent TB bacteria aren’t really latent, and how he sometimes feels like the wild-haired radical, cat-calling from the corner of the lecture hall. Ian Orme is a professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, and his research focuses on the immune response to tuberculosis (TB) — a bacterial disease that most often infects the lungs. He’s speaking at the American Society for Microbiology’s upcoming meeting on Continuing Undergraduate Education (ASMCUE). In the U.S., TB seems like a thing of the past. Here, public health measures and medical care have all but wiped out the threat from this infection. But worldwide, the WHO says there were 9.2 million new TB cases in 2006 alone, and each person with TB infects an average of 10 to 15 people with the TB bacterium every year. These are just some of the reasons Dr. Orme is delivering a talked titled “Tuberculosis: Why Now Is a Good Time to Leave the Planet” at ASMCUE. He admits leaving the planet isn’t a practical suggestion, but he wants to raise awareness of the disease and he’s not afraid to stir the pot a little. Orme and his group not only study the immune responses to TB bacteria, they’re also following a number of different avenues for developing new vaccines and improving the existing vaccine, BCG (bacille Calmette-Guérin). In this interview, I talked with Dr. Orme about his vaccine work, why he thinks latent TB bacteria aren’t really latent, and how he sometimes feels like the wild-haired radical, cat-calling from the corner of the lecture hall. tag:odeo.com,2009-05-07,24678582 Thu, 07 May 2009 11:34:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24823423-MTS26-Ian-Orme-Tuberculosis Ian Orme is a professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, and his research focuses on the immune response to tuberculosis (TB) – a bacterial disease that most often infects the lungs. He’s speaking at the American Society for Microbiology’s upcoming meeting on Continuing Undergraduate Education (ASMCUE). In the U.S., TB seems like a thing of the past. Here, public health measures and medical care have all but wiped out the threat from this infection. But worldwide, the WHO says there were 9.2 million new TB cases in 2006 alone, and each person with TB infects an average of 10 to 15 people with the TB bacterium every year. (See the WHO’s fact sheet on TB here: http://www.who.int/tb/publications/2008/factsheet_april08.pdf and http://www.who.int/tb/publications/2008/factsheet_april08.pdf. But brace yourself – this is some scary stuff.) These are just some of the reasons Dr. Orme is delivering a talke... Ian Orme is a professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, and his research focuses on the immune response to tuberculosis (TB) – a bacterial disease that most often infects the lungs. He’s speaking at the American Society for Microbiology’s upcoming meeting on Continuing Undergraduate Education (ASMCUE). In the U.S., TB seems like a thing of the past. Here, public health measures and medical care have all but wiped out the threat from this infection. But worldwide, the WHO says there were 9.2 million new TB cases in 2006 alone, and each person with TB infects an average of 10 to 15 people with the TB bacterium every year. (See the WHO’s fact sheet on TB here: http://www.who.int/tb/publications/2008/factsheet_april08.pdf and http://www.who.int/tb/publications/2008/factsheet_april08.pdf. But brace yourself – this is some scary stuff.) These are just some of the reasons Dr. Orme is delivering a talked titled “Tuberculosis: Why Now Is a Good Time to Leave the Planet” at ASMCUE. He admits leaving the planet isn’t a practical suggestion, but he wants to raise awareness of the disease and he’s not afraid to stir the pot a little. Orme and his group not only study the immune responses to TB bacteria, they’re also following a number of different avenues for developing new vaccines and improving the existing vaccine, BCG (bacille Calmette-Guérin). In this interview, I talked with Dr. Orme about his vaccine work, why he thinks latent TB bacteria aren’t really latent, and how he sometimes feels like the wild-haired radical, cat-calling from the corner of the lecture hall. Ian Orme is a professor in the Department of Microbiology, Immunology, and Pathology at Colorado State University, and his research focuses on the immune response to tuberculosis (TB) – a bacterial disease that most often infects the lungs. He’s speaking at the American Society for Microbiology’s upcoming meeting on Continuing Undergraduate Education (ASMCUE). In the U.S., TB seems like a thing of the past. Here, public health measures and medical care have all but wiped out the threat from this infection. But worldwide, the WHO says there were 9.2 million new TB cases in 2006 alone, and each person with TB infects an average of 10 to 15 people with the TB bacterium every year. (See the WHO’s fact sheet on TB here: http://www.who.int/tb/publications/2008/factsheet_april08.pdf and http://www.who.int/tb/publications/2008/factsheet_april08.pdf. But brace yourself – this is some scary stuff.) These are just some of the reasons Dr. Orme is delivering a talked titled “Tuberculosis: Why Now Is a Good Time to Leave the Planet” at ASMCUE. He admits leaving the planet isn’t a practical suggestion, but he wants to raise awareness of the disease and he’s not afraid to stir the pot a little. Orme and his group not only study the immune responses to TB bacteria, they’re also following a number of different avenues for developing new vaccines and improving the existing vaccine, BCG (bacille Calmette-Guérin). In this interview, I talked with Dr. Orme about his vaccine work, why he thinks latent TB bacteria aren’t really latent, and how he sometimes feels like the wild-haired radical, cat-calling from the corner of the lecture hall. tag:odeo.com,2009-05-07,24823423 Thu, 07 May 2009 10:14:29 -0700 no MicrobeWorld's Meet the Scientist Podcast Science, microbiology, response, who, lungs, disease, bcg, tuberculosis, Immunology, immune, tb, Pathology, CSU, asmcue, orme, latency http://www.odeo.com/episodes/25358817-MTS25-Parisa-Ariya-Bioaerosols-The-Living-Atmosphere Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she has also done a good deal of work with bioaerosols and airborne microorganisms. She will deliver a talk at the ASM General Meeting in May titled Bioaerosols - Impact on Physics and Chemistry of the Atmosphere. Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting ... Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she has also done a good deal of work with bioaerosols and airborne microorganisms. She will deliver a talk at the ASM General Meeting in May titled Bioaerosols - Impact on Physics and Chemistry of the Atmosphere. Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting new attention. We now know cells in bioaerosol particles can actively metabolize materials at interfaces, and Dr. Ariya says some of her future work will look into the details of these transformation processes and how they impact the atmosphere. In this interview, I talk with Dr. Ariya about how bioaerosols are formed, what they’re doing, and why it isn’t a good idea to use bioaerosols to manage the weather. Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she has also done a good deal of work with bioaerosols and airborne microorganisms. She will deliver a talk at the ASM General Meeting in May titled Bioaerosols - Impact on Physics and Chemistry of the Atmosphere. Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting new attention. We now know cells in bioaerosol particles can actively metabolize materials at interfaces, and Dr. Ariya says some of her future work will look into the details of these transformation processes and how they impact the atmosphere. In this interview, I talk with Dr. Ariya about how bioaerosols are formed, what they’re doing, and why it isn’t a good idea to use bioaerosols to manage the weather. tag:odeo.com,2009-04-23,25358817 Thu, 23 Apr 2009 10:34:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24920091-MTS25-Parisa-Ariya-Bioaerosols-The-Living-Atmosphere Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she has also done a good deal of work with bioaerosols and airborne microorganisms. She will deliver a talk at the ASM General Meeting in May titled Bioaerosols - Impact on Physics and Chemistry of the Atmosphere. Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting ... Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she has also done a good deal of work with bioaerosols and airborne microorganisms. She will deliver a talk at the ASM General Meeting in May titled Bioaerosols - Impact on Physics and Chemistry of the Atmosphere. Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting new attention. We now know cells in bioaerosol particles can actively metabolize materials at interfaces, and Dr. Ariya says some of her future work will look into the details of these transformation processes and how they impact the atmosphere. In this interview, I talk with Dr. Ariya about how bioaerosols are formed, what they’re doing, and why it isn’t a good idea to use bioaerosols to manage the weather. Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she has also done a good deal of work with bioaerosols and airborne microorganisms. She will deliver a talk at the ASM General Meeting in May titled Bioaerosols - Impact on Physics and Chemistry of the Atmosphere. Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting new attention. We now know cells in bioaerosol particles can actively metabolize materials at interfaces, and Dr. Ariya says some of her future work will look into the details of these transformation processes and how they impact the atmosphere. In this interview, I talk with Dr. Ariya about how bioaerosols are formed, what they’re doing, and why it isn’t a good idea to use bioaerosols to manage the weather. tag:odeo.com,2009-04-23,24920091 Thu, 23 Apr 2009 09:34:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24678583-MTS25-Parisa-Ariya-Bioaerosols-The-Living-Atmosphere Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she has also done a good deal of work with bioaerosols and airborne microorganisms. She will deliver a talk at the ASM General Meeting in May titled Bioaerosols - Impact on Physics and Chemistry of the Atmosphere. Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting ... Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she has also done a good deal of work with bioaerosols and airborne microorganisms. She will deliver a talk at the ASM General Meeting in May titled Bioaerosols - Impact on Physics and Chemistry of the Atmosphere. Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting new attention. We now know cells in bioaerosol particles can actively metabolize materials at interfaces, and Dr. Ariya says some of her future work will look into the details of these transformation processes and how they impact the atmosphere. In this interview, I talk with Dr. Ariya about how bioaerosols are formed, what they’re doing, and why it isn’t a good idea to use bioaerosols to manage the weather. Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she has also done a good deal of work with bioaerosols and airborne microorganisms. She will deliver a talk at the ASM General Meeting in May titled Bioaerosols - Impact on Physics and Chemistry of the Atmosphere. Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting new attention. We now know cells in bioaerosol particles can actively metabolize materials at interfaces, and Dr. Ariya says some of her future work will look into the details of these transformation processes and how they impact the atmosphere. In this interview, I talk with Dr. Ariya about how bioaerosols are formed, what they’re doing, and why it isn’t a good idea to use bioaerosols to manage the weather. tag:odeo.com,2009-04-23,24678583 Thu, 23 Apr 2009 09:34:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24492001-MTS25-Parisa-Ariya-Bioaerosols-The-Living-Atmosphere Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she has also done a good deal of work with bioaerosols and airborne microorganisms. She will deliver a talk at the ASM General Meeting in May titled Bioaerosols - Impact on Physics and Chemistry of the Atmosphere. Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting ... Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she has also done a good deal of work with bioaerosols and airborne microorganisms. She will deliver a talk at the ASM General Meeting in May titled Bioaerosols - Impact on Physics and Chemistry of the Atmosphere. Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting new attention. We now know cells in bioaerosol particles can actively metabolize materials at interfaces, and Dr. Ariya says some of her future work will look into the details of these transformation processes and how they impact the atmosphere. In this interview, I talk with Dr. Ariya about how bioaerosols are formed, what they’re doing, and why it isn’t a good idea to use bioaerosols to manage the weather. Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she has also done a good deal of work with bioaerosols and airborne microorganisms. She will deliver a talk at the ASM General Meeting in May titled Bioaerosols - Impact on Physics and Chemistry of the Atmosphere. Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting new attention. We now know cells in bioaerosol particles can actively metabolize materials at interfaces, and Dr. Ariya says some of her future work will look into the details of these transformation processes and how they impact the atmosphere. In this interview, I talk with Dr. Ariya about how bioaerosols are formed, what they’re doing, and why it isn’t a good idea to use bioaerosols to manage the weather. tag:odeo.com,2009-04-23,24492001 Thu, 23 Apr 2009 09:34:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24823424-MTS25-Parisa-Ariya-Bioaerosols-the-Living-Atmosphere Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she’s also done a good deal of work with bioaerosols and airborne microorganisms. She’ll deliver a talk at the ASM general meeting in May titled Bioaerosols: Impact on Physics and Chemistry of the Atmosphere.Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of ... Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she’s also done a good deal of work with bioaerosols and airborne microorganisms. She’ll deliver a talk at the ASM general meeting in May titled Bioaerosols: Impact on Physics and Chemistry of the Atmosphere.Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting new attention. We now know cells in bioaerosol particles can actively metabolize materials at interfaces, and Dr. Ariya says some of her future work will look into the details of these transformation processes and how they impact the atmosphere. In this interview, I talked with Dr. Ariya about how bioaerosols are formed, what they’re doing, and why it isn’t a good idea to use bioaerosols to manage the weather. Parisa Ariya is a professor in the Department of Atmospheric and Oceanic Sciences and the Chemistry Department at McGill University in Montreal. Dr. Ariya works mostly in atmospheric chemistry, but she’s also done a good deal of work with bioaerosols and airborne microorganisms. She’ll deliver a talk at the ASM general meeting in May titled Bioaerosols: Impact on Physics and Chemistry of the Atmosphere.Bioaerosols – microscopic clumps of microorganisms and organic debris – arise through any of a number of mechanisms. The scientific community has come full circle on the idea of microorganisms in the atmosphere, according to Dr. Ariya. Back in the early days of microbiology it was widely recognized that the air is full of living, breathing microbes, but once our understanding of atmospheric chemistry and physics matured, the roles of microbes in atmospheric processes were marginalized. Thanks, in part, to Dr. Ariya’s work, the activities and functions of bioaerosols are getting new attention. We now know cells in bioaerosol particles can actively metabolize materials at interfaces, and Dr. Ariya says some of her future work will look into the details of these transformation processes and how they impact the atmosphere. In this interview, I talked with Dr. Ariya about how bioaerosols are formed, what they’re doing, and why it isn’t a good idea to use bioaerosols to manage the weather. tag:odeo.com,2009-04-23,24823424 Thu, 23 Apr 2009 07:03:28 -0700 no MicrobeWorld's Meet the Scientist Podcast General, Science, physics, chemistry, weather, meeting, atmosphere, ASM, airborne, ariya, microorganisms, bioaerosols http://www.odeo.com/episodes/25358818-MTS24-Jeff-Bender-MRSA-in-Animals Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice at the American Society for Microbiology’s General Meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days, but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infect... Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice at the American Society for Microbiology’s General Meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days, but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infections they picked up from their owners. Fluffy might become a temporary reservoir of MRSA in your home – capable of reinfecting you and your family, but the good news is that she probably won’t be a long term carrier of the bacterium. In this interview, Dr. Merry Buckley asks Dr. Bender about MRSA in pets, whether farmers often get sick from animal-borne diseases, and whether he thinks it’s a good idea to “go organic” when shopping for food. ID3 Podcast Image courtesy of prettywar-stl on Flickr under CC 2.0. Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice at the American Society for Microbiology’s General Meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days, but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infections they picked up from their owners. Fluffy might become a temporary reservoir of MRSA in your home – capable of reinfecting you and your family, but the good news is that she probably won’t be a long term carrier of the bacterium. In this interview, Dr. Merry Buckley asks Dr. Bender about MRSA in pets, whether farmers often get sick from animal-borne diseases, and whether he thinks it’s a good idea to “go organic” when shopping for food. ID3 Podcast Image courtesy of prettywar-stl on Flickr under CC 2.0. tag:odeo.com,2009-04-17,25358818 Fri, 17 Apr 2009 09:27:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24920092-MTS24-Jeff-Bender-MRSA-in-Animals Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice at the American Society for Microbiology’s General Meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days, but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infect... Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice at the American Society for Microbiology’s General Meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days, but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infections they picked up from their owners. Fluffy might become a temporary reservoir of MRSA in your home – capable of reinfecting you and your family, but the good news is that she probably won’t be a long term carrier of the bacterium. In this interview, Dr. Merry Buckley asks Dr. Bender about MRSA in pets, whether farmers often get sick from animal-borne diseases, and whether he thinks it’s a good idea to “go organic” when shopping for food. ID3 Podcast Image courtesy of prettywar-stl on Flickr under CC 2.0. Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice at the American Society for Microbiology’s General Meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days, but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infections they picked up from their owners. Fluffy might become a temporary reservoir of MRSA in your home – capable of reinfecting you and your family, but the good news is that she probably won’t be a long term carrier of the bacterium. In this interview, Dr. Merry Buckley asks Dr. Bender about MRSA in pets, whether farmers often get sick from animal-borne diseases, and whether he thinks it’s a good idea to “go organic” when shopping for food. ID3 Podcast Image courtesy of prettywar-stl on Flickr under CC 2.0. tag:odeo.com,2009-04-17,24920092 Fri, 17 Apr 2009 08:27:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24678584-MTS24-Jeff-Bender-MRSA-in-Animals Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice at the American Society for Microbiology’s General Meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days, but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infect... Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice at the American Society for Microbiology’s General Meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days, but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infections they picked up from their owners. Fluffy might become a temporary reservoir of MRSA in your home – capable of reinfecting you and your family, but the good news is that she probably won’t be a long term carrier of the bacterium. In this interview, Dr. Merry Buckley asks Dr. Bender about MRSA in pets, whether farmers often get sick from animal-borne diseases, and whether he thinks it’s a good idea to “go organic” when shopping for food. ID3 Podcast Image courtesy of prettywar-stl on Flickr under CC 2.0. Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice at the American Society for Microbiology’s General Meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days, but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infections they picked up from their owners. Fluffy might become a temporary reservoir of MRSA in your home – capable of reinfecting you and your family, but the good news is that she probably won’t be a long term carrier of the bacterium. In this interview, Dr. Merry Buckley asks Dr. Bender about MRSA in pets, whether farmers often get sick from animal-borne diseases, and whether he thinks it’s a good idea to “go organic” when shopping for food. ID3 Podcast Image courtesy of prettywar-stl on Flickr under CC 2.0. tag:odeo.com,2009-04-17,24678584 Fri, 17 Apr 2009 08:27:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24462828-MTS24-Jeff-Bender-MRSA-in-Animals Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice at the American Society for Microbiology’s General Meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days, but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infect... Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice at the American Society for Microbiology’s General Meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days, but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infections they picked up from their owners. Fluffy might become a temporary reservoir of MRSA in your home – capable of reinfecting you and your family, but the good news is that she probably won’t be a long term carrier of the bacterium. In this interview, Dr. merry Buckley asks Dr. Bender about MRSA in pets, whether farmers often get sick from animal-borne diseases, and whether he thinks it’s a good idea to “go organic” when shopping for food. ID3 Podcast Image courtesy of prettywar-stl on Flickr under CC 2.0. Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice at the American Society for Microbiology’s General Meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days, but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infections they picked up from their owners. Fluffy might become a temporary reservoir of MRSA in your home – capable of reinfecting you and your family, but the good news is that she probably won’t be a long term carrier of the bacterium. In this interview, Dr. merry Buckley asks Dr. Bender about MRSA in pets, whether farmers often get sick from animal-borne diseases, and whether he thinks it’s a good idea to “go organic” when shopping for food. ID3 Podcast Image courtesy of prettywar-stl on Flickr under CC 2.0. tag:odeo.com,2009-04-17,24462828 Fri, 17 Apr 2009 08:27:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24823425-MTS24-Jeff-Bender-MRSA-in-Animals Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on “Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice” at the American Society for Microbiology’s general meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days (the words “E. coli O157:H7” are linked to the words “beef recall” in my mind, at least), but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organism... Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on “Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice” at the American Society for Microbiology’s general meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days (the words “E. coli O157:H7” are linked to the words “beef recall” in my mind, at least), but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infections they picked up from their owners. Fluffy might become a temporary reservoir of MRSA in your home – capable of reinfecting you and your family, but the good news is that she probably won’t be a long term carrier of the bacterium. In this interview, I asked Dr. Bender about MRSA in pets, whether farmers often get sick from animal-borne diseases, and whether he thinks it’s a good idea to “go organic” when shopping for food. Jeff Bender is a professor of veterinary public health at the University of Minnesota, and his research interests lie in the intersection of animal health and human health, including animal-borne diseases of humans, food safety, and antibiotic resistant pathogens in animals. Dr. Bender will speak on “Methicillin-resistant Staphylococcus aureus (MRSA) in Veterinary Practice” at the American Society for Microbiology’s general meeting in Philadelphia this May. To a microorganism, vertebrates can all look pretty similar. Dr. Bender’s work focuses on pathogens that can make themselves at home in both human bodies and the bodies of our pets and livestock. Outbreaks of bacterial illnesses from meat products are well publicized these days (the words “E. coli O157:H7” are linked to the words “beef recall” in my mind, at least), but the pathogens we have in common with animals don’t just travel in one direction. We humans can pass organisms and diseases to our animals, too. Dr. Bender says pets treated at veterinary clinics, for example, have come down with painful MRSA skin infections they picked up from their owners. Fluffy might become a temporary reservoir of MRSA in your home – capable of reinfecting you and your family, but the good news is that she probably won’t be a long term carrier of the bacterium. In this interview, I asked Dr. Bender about MRSA in pets, whether farmers often get sick from animal-borne diseases, and whether he thinks it’s a good idea to “go organic” when shopping for food. tag:odeo.com,2009-04-17,24823425 Fri, 17 Apr 2009 07:03:25 -0700 no MicrobeWorld's Meet the Scientist Podcast General, Food, Science, animals, Pets, 2009, organic, e coli, resistance, bacteria, veterinary, meeting, MRSA, ASM, bender, staph, Antibiotic, pathogen http://www.odeo.com/episodes/25358819-MTS23-Jo-Handelsman-The-Science-of-Bug-Guts Jo Handelsman is a professor at the University of Wisconsin, where she’s a member of the Department of Plant Pathology and chair of the Department of Bacteriology. Dr. Handelsman’s research focuses on microbial communities – their composition, how they’re structured, and how they work. Thanks to her work to improve the quality of undergraduate education, Dr. Handelsman is this year’s recipient of the American Society for Microbiology’s Carski Foundation Undergraduate Teaching Award. Dr. Handelsman has been at the cutting edge of microbial science for years. After a long time spent studying the teeming communities of microorganisms that dwell in soil, Handelsman has pared down her focus to some arguably simpler neighborhoods: the guts of insects. Handelsman applies molecular methods to identify the strains and genes present in bug guts and combines this knowledge with other information about these environments to learn what these communities might be doing. Handelsman also takes a pa... Jo Handelsman is a professor at the University of Wisconsin, where she’s a member of the Department of Plant Pathology and chair of the Department of Bacteriology. Dr. Handelsman’s research focuses on microbial communities – their composition, how they’re structured, and how they work. Thanks to her work to improve the quality of undergraduate education, Dr. Handelsman is this year’s recipient of the American Society for Microbiology’s Carski Foundation Undergraduate Teaching Award. Dr. Handelsman has been at the cutting edge of microbial science for years. After a long time spent studying the teeming communities of microorganisms that dwell in soil, Handelsman has pared down her focus to some arguably simpler neighborhoods: the guts of insects. Handelsman applies molecular methods to identify the strains and genes present in bug guts and combines this knowledge with other information about these environments to learn what these communities might be doing. Handelsman also takes a particular interest in science education, and along with her colleagues Sarah Miller and Christine Pfund, she recently co-authored Scientific Teaching, a book that outlines a dynamic research- and results-driven approach to teaching college-level science. In Dr. Merry Buckley's interview with Dr. Handelsman, they discuss about why microbiologists have a responsibility to educate almost everyone, why bacterial communities in the guts of gypsy moths might need genes for antibiotic resistance, and why and how bacteria inside of insects communicate. They also talk about the underrepresentation of women in academic research appointments and about how universities need to change to make these jobs both more available and attractive for all those brainy women who won’t (or can’t) make the jump from graduate school to academic research. Jo Handelsman is a professor at the University of Wisconsin, where she’s a member of the Department of Plant Pathology and chair of the Department of Bacteriology. Dr. Handelsman’s research focuses on microbial communities – their composition, how they’re structured, and how they work. Thanks to her work to improve the quality of undergraduate education, Dr. Handelsman is this year’s recipient of the American Society for Microbiology’s Carski Foundation Undergraduate Teaching Award. Dr. Handelsman has been at the cutting edge of microbial science for years. After a long time spent studying the teeming communities of microorganisms that dwell in soil, Handelsman has pared down her focus to some arguably simpler neighborhoods: the guts of insects. Handelsman applies molecular methods to identify the strains and genes present in bug guts and combines this knowledge with other information about these environments to learn what these communities might be doing. Handelsman also takes a particular interest in science education, and along with her colleagues Sarah Miller and Christine Pfund, she recently co-authored Scientific Teaching, a book that outlines a dynamic research- and results-driven approach to teaching college-level science. In Dr. Merry Buckley's interview with Dr. Handelsman, they discuss about why microbiologists have a responsibility to educate almost everyone, why bacterial communities in the guts of gypsy moths might need genes for antibiotic resistance, and why and how bacteria inside of insects communicate. They also talk about the underrepresentation of women in academic research appointments and about how universities need to change to make these jobs both more available and attractive for all those brainy women who won’t (or can’t) make the jump from graduate school to academic research. tag:odeo.com,2009-04-10,25358819 Fri, 10 Apr 2009 09:10:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24920093-MTS23-Jo-Handelsman-The-Science-of-Bug-Guts Jo Handelsman is a professor at the University of Wisconsin, where she’s a member of the Department of Plant Pathology and chair of the Department of Bacteriology. Dr. Handelsman’s research focuses on microbial communities – their composition, how they’re structured, and how they work. Thanks to her work to improve the quality of undergraduate education, Dr. Handelsman is this year’s recipient of the American Society for Microbiology’s Carski Foundation Undergraduate Teaching Award. Dr. Handelsman has been at the cutting edge of microbial science for years. After a long time spent studying the teeming communities of microorganisms that dwell in soil, Handelsman has pared down her focus to some arguably simpler neighborhoods: the guts of insects. Handelsman applies molecular methods to identify the strains and genes present in bug guts and combines this knowledge with other information about these environments to learn what these communities might be doing. Handelsman also takes a pa... Jo Handelsman is a professor at the University of Wisconsin, where she’s a member of the Department of Plant Pathology and chair of the Department of Bacteriology. Dr. Handelsman’s research focuses on microbial communities – their composition, how they’re structured, and how they work. Thanks to her work to improve the quality of undergraduate education, Dr. Handelsman is this year’s recipient of the American Society for Microbiology’s Carski Foundation Undergraduate Teaching Award. Dr. Handelsman has been at the cutting edge of microbial science for years. After a long time spent studying the teeming communities of microorganisms that dwell in soil, Handelsman has pared down her focus to some arguably simpler neighborhoods: the guts of insects. Handelsman applies molecular methods to identify the strains and genes present in bug guts and combines this knowledge with other information about these environments to learn what these communities might be doing. Handelsman also takes a particular interest in science education, and along with her colleagues Sarah Miller and Christine Pfund, she recently co-authored Scientific Teaching, a book that outlines a dynamic research- and results-driven approach to teaching college-level science. In Dr. Merry Buckley's interview with Dr. Handelsman, they discuss about why microbiologists have a responsibility to educate almost everyone, why bacterial communities in the guts of gypsy moths might need genes for antibiotic resistance, and why and how bacteria inside of insects communicate. They also talk about the underrepresentation of women in academic research appointments and about how universities need to change to make these jobs both more available and attractive for all those brainy women who won’t (or can’t) make the jump from graduate school to academic research. Jo Handelsman is a professor at the University of Wisconsin, where she’s a member of the Department of Plant Pathology and chair of the Department of Bacteriology. Dr. Handelsman’s research focuses on microbial communities – their composition, how they’re structured, and how they work. Thanks to her work to improve the quality of undergraduate education, Dr. Handelsman is this year’s recipient of the American Society for Microbiology’s Carski Foundation Undergraduate Teaching Award. Dr. Handelsman has been at the cutting edge of microbial science for years. After a long time spent studying the teeming communities of microorganisms that dwell in soil, Handelsman has pared down her focus to some arguably simpler neighborhoods: the guts of insects. Handelsman applies molecular methods to identify the strains and genes present in bug guts and combines this knowledge with other information about these environments to learn what these communities might be doing. Handelsman also takes a particular interest in science education, and along with her colleagues Sarah Miller and Christine Pfund, she recently co-authored Scientific Teaching, a book that outlines a dynamic research- and results-driven approach to teaching college-level science. In Dr. Merry Buckley's interview with Dr. Handelsman, they discuss about why microbiologists have a responsibility to educate almost everyone, why bacterial communities in the guts of gypsy moths might need genes for antibiotic resistance, and why and how bacteria inside of insects communicate. They also talk about the underrepresentation of women in academic research appointments and about how universities need to change to make these jobs both more available and attractive for all those brainy women who won’t (or can’t) make the jump from graduate school to academic research. tag:odeo.com,2009-04-10,24920093 Fri, 10 Apr 2009 08:10:04 -0700 no MicrobeWorld's Meet the Scientist Podcast http://www.odeo.com/episodes/24435584-MTS23-Jo-Handelsman-The-Science-of-Bug-Guts Jo Handelsman is a professor at the University of Wisconsin, where she’s a member of the Department of Plant Pathology and chair of the Department of Bacteriology. Dr. Handelsman’s research focuses on microbial communities – their composition, how they’re structured, and how they work. Thanks to her work to improve the quality of undergraduate education, Dr. Handelsman is this year’s recipient of the American Society for Microbiology’s Carski Foundation Undergraduate Teaching Award. Dr. Handelsman has been at the cutting edge of microbial science for years. After a long time spent studying the teeming communities of microorganisms that dwell in soil, Handelsman has pared down her focus to some arguably simpler neighborhoods: the guts of insects. Handelsman applies molecular methods to identify the strains and genes present in bug guts and combines this knowledge with other information about these environments to learn what these communities might be doing. Handelsman also takes a pa... Jo Handelsman is a professor at the University of Wisconsin, where she’s a member of the Department of Plant Pathology and chair of the Department of Bacteriology. Dr. Handelsman’s research focuses on microbial communities – their composition, how they’re structured, and how they work. Thanks to her work to improve the quality of undergraduate education, Dr. Handelsman is this year’s recipient of the American Society for Microbiology’s Carski Foundation Undergraduate Teaching Award. Dr. Handelsman has been at the cutting edge of microbial science for years. After a long time spent studying the teeming communities of microorganisms that dwell in soil, Handelsman has pared down her focus to some arguably simpler neighborhoods: the guts of insects. Handelsman applies molecular methods to identify the strains and genes present in bug guts and combines this knowledge with other information about these environments to learn what these communities might be doing. Handelsman also takes a particular interest in science education, and along with her colleagues Sarah Miller and Christine Pfund, she recently co-authored Scientific Teaching, a book that outlines a dynamic research- and results-driven approach to teaching college-level science. In Dr. Merry Buckley's interview with Dr. Handelsman, they discuss about why microbiologists have a responsibility to educate almost everyone, why bacterial communities in the guts of gypsy moths might need genes for antibiotic resistance, and why and how bacteria inside of insects communicate. They also talk about the underrepresentation of women in academic research appointments and about how universities need to change to make these jobs both more available and attractive for all those brainy women who won’t (or can’t) make the jump from graduate school to academic research. Jo Handelsman is a professor at the University of Wisconsin, where she’s a member of the Department of Plant Pathology and chair of the Department of Bacteriology. Dr. Handelsman’s research focuses on microbial communities – their composition, how they’re structured, and how they work. Thanks to her work to improve the quality of undergraduate education, Dr. Handelsman is this year’s recipient of the American Society for Microbiology’s Carski Foundation Undergraduate Teaching Award. Dr. Handelsman has been at the cutting edge of microbial science for years. After a long time spent studying the teeming communities of microorganisms that dwell in soil, Handelsman has pared down her focus to some arguably simpler neighborhoods: the guts of insects. Handelsman applies molecular methods to identify the strains and genes present in bug guts and combines this knowledge with other information about these environments to learn what these communities might be doing. Handelsman also takes a particular interest in science education, and along with her colleagues Sarah Miller and Christine Pfund, she recently co-authored Scientific Teaching, a book that outlines a dynamic research- and results-driven approach to teaching college-level science. In Dr. Merry Buckley's interview with Dr. Handelsman, they discuss about why microbiologists have a responsibility to educate almost everyone, why bacterial communities in the guts of gypsy moths might need genes for antibiotic resistance, and why and how bacteria inside of insects communicate. They also talk about the underrepresentation of women in academic research appointments and about how universities need to change to make these jobs both more available and attractive for all those brainy women who won’t (or can’t) make the jump from graduate school to academic research. tag:odeo.com,2009-04-10,24435584 Fri, 10 Apr 2009 08:10:04 -0700 no MicrobeWorld's Meet the Scientist Podcast